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Characterization of Novel CB2 Agonist SMM-295 and Its Effects in Ischemia/
Reperfusion Injury
Abstract
Acute kidney injury (AKI) is a major problem clinically affecting up to two-thirds of intensive care unit
patients, and results in increased hospitalization time, the risk of developing chronic kidney disease, and
mortality. Hallmarks of AKI include tubular cell death and a decrease in renal perfusion which leads to
decreases in renal function following injury. For 20 years the pathophysiology of AKI has been well
established. However, therapies for AKI have shown minimal to no success clinically. The work here
describes our efforts to further categorize the effects of CB2 activation, a possible novel therapeutic
target in AKI.
There is increasing importance associated with the understanding of the biological activity of the
cannabinoid receptors following the increased acceptance in the medicinal purposes of cannabis and
cannabis-related compounds. The endocannabinoid system is comprised of its cognate G-protein
coupled receptors, cannabinoid type 1 and 2 receptors, endogenous lipid signaling molecules, Narachidonoyl ethanolamine (AEA) and 2-acylglycerol, and the enzymes involved in their biosynthesis and
catabolism. In the kidney, the CB1 receptors consistently demonstrate deleterious effects on glomerular
and tubular function in various acute and chronic forms of injury, while CB2 receptors have demonstrated
the opposite effects.
This work will demonstrate the findings of studies that focus on the role of CB2 in the recovery from
ischemia/reperfusion injury (IRI) and the effects of CB2 activation on both tubular cell death and renal
hemodynamics. To study the effect of CB2 activation on renal damage following IRI, our scientific group
tested a small molecule agonist, SMM-295 [3′-methyl-4-(2-(thiophen-2-yl) propan-2-yl) biphenyl-2,6-diol], in
an investigation of the CB2 receptor as a potential therapeutic target in the prevention of tubular epithelial
cell damage after AKI. To test this compound in AKI, we used a mouse model of renal bilateral ischemiareperfusion injury (IRI), which is a common experimental model to study AKI, demonstrating considerable
beneficial effects of SMM-295 following injury. Subsequently, we then investigated the possible
mechanisms that undermine the effects of SMM-295, including initiation of antiapoptotic signaling
cascades in tubular epithelium as well as increases in renal perfusion through a vascular effect
demonstrating a multifunctional role for SMM-295 in the treatment of IRI.
Our findings demonstrate that CB2 activation by SMM-295 ameliorated the effects of IRI through
decreased tubular cell death in proximal tubule cells along with an increase in renal perfusion through a
direct vascular effect. These data indicate selective activation of the CB2 receptor by our novel CB2
agonist SMM-295 has therapeutic value in pre-clinical studies and may provide a new target for therapy in
the treatment of AKI.
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ABSTRACT
Acute kidney injury (AKI) is a major problem clinically affecting up to two-thirds
of intensive care unit patients, and results in increased hospitalization time, the risk of
developing chronic kidney disease, and mortality. Hallmarks of AKI include tubular cell
death and a decrease in renal perfusion which leads to decreases in renal function
following injury. For 20 years the pathophysiology of AKI has been well established.
However, therapies for AKI have shown minimal to no success clinically. The work here
describes our efforts to further categorize the effects of CB2 activation, a possible novel
therapeutic target in AKI.
There is increasing importance associated with the understanding of the biological
activity of the cannabinoid receptors following the increased acceptance in the medicinal
purposes of cannabis and cannabis-related compounds. The endocannabinoid system is
comprised of its cognate G-protein coupled receptors, cannabinoid type 1 and 2 receptors,
endogenous lipid signaling molecules, N-arachidonoyl ethanolamine (AEA) and 2acylglycerol, and the enzymes involved in their biosynthesis and catabolism. In the
kidney, the CB1 receptors consistently demonstrate deleterious effects on glomerular and
tubular function in various acute and chronic forms of injury, while CB2 receptors have
demonstrated the opposite effects. This work will demonstrate the findings of studies that
focus on the role of CB2 in the recovery from ischemia/reperfusion injury (IRI) and the
effects of CB2 activation on both tubular cell death and renal hemodynamics.
To study the effect of CB2 activation on renal damage following IRI, our
scientific group tested a small molecule agonist, SMM-295 [3′-methyl-4-(2-(thiophen-2yl) propan-2-yl) biphenyl-2,6-diol], in an investigation of the CB2 receptor as a potential
therapeutic target in the prevention of tubular epithelial cell damage after AKI. To test
this compound in AKI, we used a mouse model of renal bilateral ischemia-reperfusion
injury (IRI), which is a common experimental model to study AKI, demonstrating
considerable beneficial effects of SMM-295 following injury. Subsequently, we then
investigated the possible mechanisms that undermine the effects of SMM-295, including
initiation of antiapoptotic signaling cascades in tubular epithelium as well as increases in
renal perfusion through a vascular effect demonstrating a multifunctional role for SMM295 in the treatment of IRI.
Our findings demonstrate that CB2 activation by SMM-295 ameliorated the
effects of IRI through decreased tubular cell death in proximal tubule cells along with an
increase in renal perfusion through a direct vascular effect. These data indicate selective
activation of the CB2 receptor by our novel CB2 agonist SMM-295 has therapeutic value
in pre-clinical studies and may provide a new target for therapy in the treatment of AKI.
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CHAPTER 1.

INTRODUCTION

The kidney functions as the filter of the body and is comprised of two principal
regions: the renal cortex and the medulla (1). The cortex consists of the renal corpuscles,
the proximal convoluted tubules, and distal convoluted tubules. The nephron starts in the
cortex and are categorized into two groups, cortical and juxtamedullary nephrons, based
on the distance they extend into the medulla. Cortical nephrons have short loops of Henle
that do not infiltrate beyond the cortex while juxtamedullary nephrons have longer loops
that extend deep into the tip of the medulla. The medulla contains columns of connective
tissue that extend downward from the cortex through this region separating the renal
pyramids and renal papillae. The renal papillae consist of collecting ducts grouped in
bundles that transfer urine made by the nephron for excretion. The cortex has increased
oxygen levels compared to the medulla, making these two regions both structurally and
metabolically different. This phenomenon has further implications in AKI resulting in
protection from the long-lasting damage from AKI. Meanwhile, the medulla remains
sensitive to injury following a biological insult. A third region of the kidney is called the
renal hilum which functions as the entry and exit site for the kidneys such as blood,
lymphatic vessels, nerves, and ureters. The kidney functions as the filter of the body
eliminating waste and working to maintain homeostasis of the body by interacting with
multiple organ systems. These functions are primarily achieved through four
mechanisms: 1) filtration, 2) reabsorption, 3) secretion and 4) hormone release.
Filtration begins at the glomerulus which is the transition point between the
systemic blood flow and the primary functional unit of the kidney, the nephron. The
delivery of blood to the kidney influences the rate of filtration with each of these
branches being fundamental in the overall renal function. The nephron is perfused with
blood entering the glomerulus from the afferent renal arterioles. Efferent arterioles allow
for the blood to exit the glomerulus and combine with the afferent arterioles, which
regulates the overall perfusion of filtrate into the nephron which is also called glomerular
filtration rate or GFR. Through vascular constriction or vasodilation, the afferent and
efferent arterioles can control the pressure within the glomerulus and thus regulate the
overall GFR. GFR increases when the afferent arterioles are vasodilated, and the efferent
arterioles are vaso-constricted. This control mechanism is vital for the normal function of
the kidney as maintaining GFR is a necessary first step in all other renal functions. The
filtrate perfuses across the glomerulus capillaries lined with specialized cells called
podocytes which function to filter the blood through specialized filtration slits created by
dedicated processes on these cells called pedicels. The resulting glomerular filtrate is
determined by the structure of these cells and electrical charge of the collagen protein
molecules that line the filtration barrier making glomerular filtration both size and charge
selective. The filtrate is then carried through the proximal tubules to the loop of Henle
and ultimately to the distal tubules and collecting ducts. During this transit, multiple
substrates are exchanged between the nephron and surrounding microvasculature which
function to control absorption and secretion of water, waste, and other nutrients.
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The proximal tubule acts as the primary site of absorption and secretion in the
nephron. This includes the intake of salt, water, organic solutes (i.e., glucose and amino
acids), potassium, urea, phosphate, and citrate. Secretion of most types of medications
and ammonium formed through the breakdown of glutamine to alpha-ketoglutarate and
ultimately bicarbonate anions occur in the proximal tubule. These processes are driven
primarily by active transport and co-transport mechanisms that require ATP. Therefore,
the proximal tubules have high metabolic needs. The loop of Henle is unique in its
structure and functions to create a concentration gradient in the medulla of the kidney.
This gradient is produced by electrolyte pumps and serves to control the concentration of
urine through the regulation of water reabsorption. The nephron concludes with the
collecting ducts which, as their name implies, collect and combine to carry the filtrate to
the ureters where it continues to the bladder for excretion.

Acute Kidney Injury
A critical function of the kidney is its ability to filter and excrete nitrogenous
waste products from the blood. In AKI there is a rapid decline in GFR resulting in
increases in nitrogenous waste products, primarily blood urea nitrogen and creatinine (25). Currently, these values are used in the clinic to categorize AKI in patients; however,
improved methods are needed due to the impreciseness of these surrogate markers for
GFR. The causes of this decline in GFR are grouped into three primary categories: prerenal, renal, and postrenal, which will be discussed briefly here.
The kidneys receive 20-25% of total cardiac output which acts to maintain
adequate renal perfusion and GFR (6). Prerenal conditions contributing to AKI are
categorized by decreased renal perfusion without damage to the renal parenchyma,
known as prerenal azotemia. Prerenal azotemia is commonly caused by hypovolemia
resulting from several clinical conditions seen in hospital patients including diarrhea,
excessive sweating, sepsis, burns, and impaired cardiac output (6). In response to prerenal
conditions the kidney must act to concentrate the urine and reabsorb sodium to restore
normal renal perfusion. Current therapies aimed at restoring renal perfusion have shown
to promptly improve renal function, which further demonstrates the importance of renal
hemodynamics in the recovery of AKI (7).
The kidney is particularly sensitive to a wide variety of insults, thus making renal
causes of AKI challenging to describe. Therefore, it is often helpful to consider the
damage to four distinct structures within the kidney separately when characterizing
intrinsic renal failure: 1) tubules, 2) glomeruli, 3) the interstitium, and 4) the entry renal
blood vessels. AKI resulting from tubular damage is also known as acute tubular necrosis
(ATN) and is attributed to two significant clinical causes: 1) ischemic injury resulting
from a loss of renal perfusion, and 2) nephrotoxic injury resulting from toxic genus
compounds usually from pollutants or medicines. Glomerulonephritis occurs as part of
other systemic diseases including lupus or Wagner’s granulomatosis characterized by
glomerular damage (8, 9). In severe cases of acute glomerulonephritis, AKI from
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glomerular injury can occur. Infections or allergic reactions to a variety of medications
can cause acute interstitial nephritis, categorized by interstitial damage in the kidney,
which in severe cases can develop into AKI (8, 9). Furthermore, an intra-renal vascular
injury leading to decreases in renal perfusion that diminish GFR can also cause AKI.
Common causes of this type of vascular injury include preeclampsia, hypertension, and
atherosclerosis (8, 9).
Postrenal causes of AKI are categorized by an obstruction of the output of the
kidney usually in terms of urinary flow. The effect of any urinary tract obstruction
increases the tubular pressure and thus decreases GFR independent of any compensatory
mechanisms. Furthermore, inflammation due to this obstruction can further contribute to
diminishing GFR (10-14). Causes of post-renal AKI include prostatic hyperplasia,
prostate cancer in men, cervical cancer in women, and ureteral stones (15).
The critical component common to all three types of renal injury is the decrease in
GFR caused by a reduction in renal perfusion and a loss of renal function. The
mechanisms that underlie the recovery of nephron structures and the hemodynamic
response of the kidney following AKI are paramount in the discovery of novel
therapeutics aimed to aid in the recovery of AKI. The next few sections of this
introduction to AKI will focus on the pathophysiology of acute to necrosis in the
hemodynamic changes that occur during AKI, the cellular responses to injury, and the
mechanisms of renal recovery following AKI.
Acute Tubular Necrosis
Clinically, ATN and the associated decrease in GFR is generally divided into four
phases: initiation, extension, maintenance, and recovery phases (2). While ATN correctly
identifies the site of injury this terminology is somewhat misleading because few renal
epithelial cells undergo necrosis with most tubular epithelial cells facing some degrees of
sublethal cellular damage. Although there is no simple explanation between tubular
injury and the fall in GFR, there are three proposed mechanisms through which this effect
could be mediated, which include vasoconstriction of afferent arterioles in response to
tubuloglomerular feedback, back leak of glomerular filtrate, and tubular obstruction (6).
Initiation of ATN occurs when reductions in renal blood flow result in severe
cellular ATP depletion which leads to acute cell injury and dysfunction. Inner sections of
the kidney, namely the cells of the S3 segment of the outer medulla and TAL, have high
rates of solute transport and abundant mitochondria. These segments also exist in a low
oxygen environment under normal physiological conditions which further predisposes
these areas to damage from any further localized decreases in oxygen. The proximal
tubule cells located in these areas have unusually high metabolic needs and thus are
injured in more significant numbers than other tubular cell types in the kidney during
renal insult. Renal tubular cell damage is a critical feature characterized by a disruption
of the standard framework within the cell (8, 16, 17). The severity and duration of
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ischemic injury dictate the extent of these alterations, which usually are sublethal, lead to
malfunctioning renal tubular appeal cells and renal vascular endothelial cells.
The activation phase consists of epithelial and endothelial cells initiating an upregulation of a variety of cytokines that activate an inflammatory cascade (18). The
extent to which the immune system plays a role in AKI has not been fully described but
there is indication of its role in the disease. Therapies aimed at decreasing oxidative stress
and immune system response have shown some preclinical success. For our project, we
focused on localized epithelial and endothelial cell changes within the kidney irrespective
of immune cell infiltration.
Following the activation phase, there is continued hypoxia after the initial
ischemic event and an inflammatory response brought on by the release of cytokines (6).
These two events are more pronounced in the cortical medullary junction of the kidney
and constitute the majority of the extension phase. During this phase there is a severe
reduction in blood flow, accumulation of red and white blood cells, and vascular
endothelial cell damage that can contribute to the continued ischemia in the kidney. The
sustained ischemia leads to continued cell injury and death (i.e., necrosis and apoptosis)
in the outer medulla (19). However, in the cortex where blood flow rapidly returns to
normal levels, the tubular epithelial cells in this region can undergo cellular repair during
this phase (6). Regardless of the recovery occurring in the cortex, medullary cells
continue to respond to prolonged ischemic conditions resulting in an increased cell death
through programmed cell death pathways, primarily apoptosis. Loss of the cells in this
area contribute to further decreases in GFR and continued production of chemokines and
cytokines that further enhance the immune response (20). These events happen within the
first 24 hours following injury, and the messengers for the systems responsible for these
effects appear in as little as two hours after the initial ischemic event (21-23). Dead
tubular cells then start to collect in the tubular lumen causing loss of renal function and a
further localized reduction in renal perfusion.
The maintenance phase of AKI occurs before the recovery phase and is where
cells undergo repair, migration, proliferation, and apoptosis to reestablish tubular
integrity (6). During this phase, the GFR remains stable; however, it is lowered
proportional to the extent of the injury. These events contribute to improving cellular
function through reorganization and repair of the structures and provide normalized blood
flow to establish intra- and intercellular homeostasis. Following the maintenance phase,
the recovery phase consists of further cellular differentiation, reestablishment of
epithelial polarity, and the return to normal cellular and organ function (8, 24, 25). These
phases of AKI focus on the extent to which renal epithelial cells are damaged and
respond to ischemic injury. Alongside these events, there are concurrent hemodynamic
changes that occur to the vasculature and microvasculature of the kidney.
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Hemodynamic Changes
AKI was initially characterized as a vasomotor neuropathy defined by a sustained
increase in renal vascular resistance that attributed to factors including sympathetic
nervous system input, prostaglandin synthesis, and alterations in vascular function
secondary to injury, the altered production response to vasoconstrictors or vasodilators
(26). The underlying impairment of hemodynamic regulation in renal disease directly
contributes to the reduction in GFR seen in AKI (26-28). Alterations in vascular function
secondary to injury may occur with direct damage to the renal vasculature. The
microvasculature is compromised with ischemic injury leading to further imbalances of
oxygen supply. AKI effects on renal vascular include increased permeability, interstitial
edema, vasoconstriction, and vascular occlusion causing an overall decrease in blood
flow to the organ. Furthermore, oxidative stress and vasoconstrictive prostaglandin
production from injured tubules negatively impact oxygen delivery, which leads to a
local “no-reflow” phenomenon that can exacerbate the initial injury. The vasoconstrictive
effect seen in this phenomenon is caused by changes in sympathetic nervous activity and
prostaglandin production which increase the complications of AKI.
Sympathetic nervous activity induces increases in renal vascular resistance during
AKI to mitigate the effects of hypotension or reductions in circulating plasma. There are
elevated levels of norepinephrine, and renal venous blood following ischemic injury and
studies demonstrate direct infusion of norepinephrine into the renal artery can lead to
AKI through reductions of renal blood flow (29). Furthermore, denervation of the
kidneys attenuates the effects of AKI through an improvement in renal blood flow (3032). While there is strong evidence for a direct consequence of norepinephrine and renal
vascular resistance, increased norepinephrine levels lead to renin secretion and ultimately
production of angiotensin II. However, angiotensin II activity may play a role in AKI
following clinical evidence of increased risk of AKI in patients receiving ACE inhibitors
following cardiac surgery (33, 34). While renin levels are increased in patients with AKI,
there is still limited information about the role of renin in the disease (35, 36). Therapies
aimed to decrease norepinephrine levels, and thus sympathetic nervous activity may
prove advantageous clinically in the future.
Lipid-derived signaling molecules called Prostaglandins are produced locally and
the generation of these molecules has implications in AKI. Prostaglandins are a group of
arachidonic acid-derived lipid signaling molecules that are synthesized by the activity of
the cyclooxygenase enzyme. The primary prostaglandins produced in the kidneys,
include PGI2, PGE2, PGF2, PGD2, and TxA2. These prostaglandins play a pivotal role
in maintaining renal perfusion during episodes of ischemia. Cyclooxygenase inhibitors,
particularly for the inducible form (COX-2), represent a major cause of increased risk
factor in hospitalized patients for AKI (37, 38).
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Cell Death in AKI
Tubular epithelial cells act to survive the insult and contribute to the early stages
of renal function and recovery. Cells that are able to recover from the initial insult must
work to provide some level of renal function following injury. Cells that are not able to
recover from the initial injury or are damaged further in the later phases of recovery
following AKI die through multiple cell death pathways including apoptosis, necrosis,
ferropoptosis, pyroptosis, and in some incidences autophagy (6). Apoptosis is the primary
mechanism of cell death in early stages of recovery from AKI particularly in the proximal
tubular cells. Therefore, this section will highlight mechanisms predominantly mediating
apoptosis and their involvement in AKI.
Apoptosis is a form of cell death that plays a role in normal cell turnover within
the body distinguishing it from necrotic cell death in that processes involved in apoptosis
are very ordered and mediated by pre-existing enzyme cascades (39). Apoptotic cell
death occurs rapidly in response to ischemia in the kidney with evidence of occurrence in
rats as early as 15 minutes following ischemic conditions. It is hard to determine the
exact extent through which apoptosis occurs following AKI due to the differences in
conditions between various models of the disease. However, several studies have shown
that by blocking apoptosis as a beneficial effect on kidney function following injury. In
this section, the initiation of apoptotic signaling in the pathways through which this is
achieved will be discussed.
In terms of apoptotic cell death cysteine-aspartic proteases, or caspases, which are
constitutively expressed are activated in response to a variety of apoptotic factors. These
caspases act as either initiators or effectors of cell death cascades. Initiator caspases
function to sense the apoptotic signal, self-activate, and activate effector caspases. Then
effector caspases activate pathways resulting in an orderly destruction of the injured cell.
Initiator caspases are activated by either extrinsic or intrinsic factors with either of these
signal outputs converging on common effector caspases (40-42). Activation of the
extrinsic factors occurs in AKI often as a secondary effect to the initial injury and can be
activated by pro-inflammatory cytokines. The intrinsic pathway of apoptosis is
responsive to self-stress and activated by oxidative stress commonly seen in ischemic
injury among other forms of AKI (6). Features of this pathway include the release of
mitochondrial apoptogenic substances, including cytochrome C and the interaction of the
BCL-2 family of proteins, which function to stabilize the mitochondrial membrane
preventing this release. Several studies have shown beneficial effects of activation and
expression of members of the BCL-2 family of proteins in various models of AKI
demonstrating that by preventing apoptosis there is a practical benefit for the kidney
initially following injury (43).
Tubular Repair and Regeneration
Sub-lethally damaged tubular epithelial cells initiate a series of pathways in
response to AKI to repair from damage induced during injury and regenerate to restore
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proper organ function. Classically, three groups of genes have been associated with the
response to renal injury in tubular epithelial cells. These groups comprise what is known
as the renal stress response and include heme oxygenase, heat shock proteins, and stressactivated protein kinases (6). In this section, these classical groups of proteins will be
discussed.
Heme oxygenase has two isoforms that have been characterized (HO-1 and HO2). HO-1 is the inducible form of the enzyme and mediates the first step of heme
catabolism (44). HO-1 is induced in the early stages of ischemia-reperfusion injury and is
generally associated with cryoprotection (45-47). Impairment of HO-1 activity has been
shown to worsen renal function following ischemia-reperfusion injury in multiple studies
(46, 48-51). Additionally, induction of HO-1 a physiologic priming or viral delivery of
HO-1 expressing gene protects tubular cells from damage (52, 53). Moreover, the
production of carbon monoxide which is a byproduct of HO-1 activity has vasodilators
were effects potentially on the renal vasculature that could lead to a restoration of blood
flow (52).
Heat shock proteins are associated with the recovery of the cytoskeletal structure
following injury (54). In fact, overexpression of either HSP-72 or HSP-27 preserves the
changes that occur to the cytoskeleton following ATP depletion seen in AKI (55, 56).
Additionally, this family of proteins is associated with the inhibition of cell signaling
pathways leading towards cell death (57). In models of mitochondrial injury, HSP-27
provides a protective role through its interaction with the Bax protein (58). Heat shock
protein family members may also have antioxidant and vasodilatory properties. HSP-70,
for example, prevents increases in superoxide production, and HSP-90 preserves NO
synthesis following injury (59, 60). These processes may contribute to decreases in
antioxidant stress either directly or through increased blood flow to the region. While
much is known about heat shock proteins, there is a lack of information about their role
in AKI other than their overexpression following injury.
Stress-activated protein kinases make up another group of proteins expressed in
tubular epithelial cells following AKI (61-63). These proteins called mitogen-activated
protein kinases (MAPKs), traditionally respond to cellular stress due to DNA damaging
agents and reactive oxygen species. This family of kinases includes both the extracellular
related protein kinases (ERKs) and stress-activated protein kinase (SAPK). While both of
these classes of kinases show clear function in the recovery of the kidney following AKI
in multiple studies (61, 64), one of these proteins, ERKs, also play a role in induction of
apoptotic cell death (65). In theory this should further worsen the effects of AKI creating
a conflict in our understanding of this pathways role in the recovery from renal injury.
Following these initial regulations of protein families associated with the recovery
of the kidney following AKI, there is a peak of proliferative activity of proximal tubules
(2). Studies in cultured proximal tubular cells demonstrate proliferative activity in
response to epidermal growth factor, hepatocyte growth factor, insulin-like growth factor,
and fibroblast growth factors which are produced both locally and systemically (66-69).
However, clinical trials aimed to promote renal recovery following AKI utilizing these
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growth factors have not proven lucrative (70). The dedifferentiation and proliferation of
proximal tubular cells are imperative to the restoration of the kidney following AKI. It is
through a concert of protein chaperones, cell cycle signaling transcription factors, and
growth factors that this effect is achieved (2).
Because of the inability to integrate the information known about the signaling
pathways to produce a therapeutic to treat AKI, further studies are essential to provide
more information about AKI to move the field towards developing therapeutic targets.
Some examples in the past several years are intrinsic proteins, such as accessory proteins
(e.g. AGS3 (71), TRIP13 (72) etc.) and GPCRs (e.g. APJ (73), Rho (74), etc.) , or
extrinsic cells from the immune system (75).
Cannabinoids and AKI
GPCRs and other heterotrimeric G-proteins are continuing to emerge as new
therapeutic targets for kidney diseases, including AKI. Increasingly the role of the
cannabinoid system is being uncovered as research into the peripheral effects of
cannabinoids grows. Currently, the laws regarding the use of cannabis, which contains
significant concentrations of exogenous cannabinoids, are changing in the United States
leading to increased access to these substances nationwide. This recent change in public
policy has increased the urgency to uncover the effects of cannabinoid signaling across
multiple models of disease including AKI. There are limited studies into the cannabinoid
systems effect in renal injury, however, these studies demonstrate a potential role for the
endocannabinoids and the cannabinoid system in the recovery from renal disease (76-82).
The role of the endocannabinoid system in the kidney after activation of its
cognate G protein-coupled receptors, cannabinoid receptors 1 and 2 (CB1 and CB2,
respectively), is continuing to emerge as a central response system after injury stimuli to
the kidney (83). Recent studies demonstrate an emerging role of the CB2 activation in the
kidney in CKD and AKI (83). Studies have determined a beneficial role for CB2
activation following renal injury with selective activation of the CB2 receptor protecting
renal architecture and nephron function by mitigating the nephropathic effects associated
with diabetes or diet-induced obesity in rodent models of CKD (79, 82, 84). Diabetic
nephropathy was attenuated after treatment with the natural product CB2 receptor agonist
β-caryophyllene or a small molecule analog functioning as a CB2 agonist (79). Similarly,
CB2 receptor activation in rodents with diet-induced obesity ameliorated their
progression toward renal dysfunction. Conversely, CB2 receptor antagonists reduced
renal function, as measured by creatinine clearance, which suggests that renal failure was
exacerbated.
While some data is suggesting CB2 activation is beneficial in renal function in
other models of kidney disease, specifically AKI (78, 79, 82, 84) , little evidence has
demonstrated a clear mechanism through which CB2 activation leads to decrease in renal
damage following IRI. Currently, there is limited data into the CB1 and CB2 receptor
expression in the kidney (83, 85, 86). Previous studies demonstrate CB1 and CB2
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expression in the kidney during normal and pathological conditions (87-92) . It is known
that the CB1 receptors are expressed in high abundance with a reasonably broad
localization pattern, which includes all segments of the nephron and vasculature. The
expression profile of cnr2 mRNA is somewhat more limited, as it appears to be localized
to the proximal tubular epithelial cells in the renal cortex (83). More importantly,
however, there is differential expression profiling of the Cnr1 and Cnr2 mRNA in the
kidney and in rodent models of AKI. Interestingly, Cnr2 mRNA increases while Cnr1
mRNA remains unchanged indicating a role of CB2 and not CB1 in the recovery of the
kidney following AKI (83, 85, 86). Our findings (shown in Chapter 2) are consistent with
this fact and demonstrate increased levels of Cnr2 mRNA that encodes for the CB2
receptor in whole kidney lysates following IRI suggesting a role of the CB2 receptor in
the recovery from IRI (93).
The precise nature of the role of the cannabinoid receptors in the kidney during
AKI remains to be fully understood. Few studies over the last decade have investigated
the effects of CB2 activation following AKI. These studies demonstrate CB2 activation
following both ischemic and nephrotoxic models of AKI provide beneficial therapeutic
effects (76, 79-82). There is abundant evidence that CB2 activation leads to improved
renal outcomes following nephrotoxic insult with cisplatin (79-82). These studies suggest
that decreases in oxidative stress and immune cell infiltration are driving the effects seen
in CB2 agonist treated animals. In IRI the evidence demonstrates a protective effect on
renal architecture following IRI (76). These studies failed to address the exact
mechanisms through which tubular epithelial cells are intrinsically protected from cell
death. Furthermore, these studies did not investigate at an important component of AKI,
the loss of renal perfusion and changes in renal hemodynamics. Cannabinoids have been
implemented in systemic vascular changes and are gaining considerable interest as
modulators of vascular resistance throughout the body and potentially in the kidney.
Cannabinoid activation has hemodynamic effects throughout the body with CB1/2
activation leading to systemic or localized changes in blood flow making these receptors
prime targets for therapeutic intervention of hypoperfusion based diseases like renal IRI.
To date, there is a lack of studies investigating a role of the cannabinoid receptors on the
regulation of renal hemodynamics, and the activity of these receptors even under normal
conditions remains poorly understood. What is evident through the following studies
mentioned is that the effects of CB1 and CB2 activation generally contradict each other
having opposing effects in rodents. Early rat studies implicated that anandamide (AEA)
increased renal blood flow with a concomitant reduction in glomerular filtration rate by
preferential vasodilation of the efferent arteriole via CB1 receptor activation (94). Other
studies from Deutsch et al. demonstrate that segments of the renal and arcuate arteries
were capable of dilating in the presence of AEA (90). CB1 receptor using a synthetic
agonist either demonstrated renal vasoconstriction or was associated with increased blood
flow changes and urine excretion, however, through a non-CB1 dependent mechanisms
(95). The data suggests CB1 activation leads to localized renal vasoconstriction while
selective CB2 receptor activation generally demonstrates opposite effects in the kidney
seen by the CB1 receptor. Therefore, CB2 activation following renal injury may act to
protect renal function in the glomerulus and integrity of the renal tubules. It is important
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to note this opposing effect of CB1 and CB2 activation on renal vascular resistance
following AKI. It is known that CB1 activation can lead to modulation of sodium ion
channels that would perturb function of the tubular epithelial function and prove
deleterious for the kidney following injury (96). Therefore, it is paramount that
therapeutic strategies aimed at the cannabinoid access have specificity between the two
receptors through their various signaling outputs in the cell following activation.
Cellular Mechanisms of CB2 Receptor Activation
Extensive research efforts have gone into elucidating the molecular activation
mechanisms of the cannabinoid receptors. Cannabinoid receptors, like other GPCR’s,
when activated facilitate the exchange of GDP for GTP associated with the Gα subunit
enabling it to disassociate from the Gβγ subunit with each of these subunits able enact
downstream changes in the cell. While these signal transduction pathways are not
activated in isolation and are generally a constellation of activity, the next paragraph will
describe the effects of CB2 receptor activation in the context of two well established
GPCR transduction pathways: heterotrimeric G-protein signaling and β-arrestin cascades.
The CB1 receptor shows some promiscuity between Gα subtypes, however, the
CB2 receptor preferentially couples to Gαi (97-99). Gαi activity leads to decreases in
cAMP levels leading to further downstream changes including activation of kinases
including PKA and various downstream mechanisms. Many signaling outputs of CB2 are
sensitive to pertussis toxin indicating a role of Gαi in these cascades (83, 100). Upon
activation of CB2 Gαi coupling adenylyl cyclase is inhibited and mitogen-activated
protein kinase and extracellular kinase-1 and -2 are activated (101-103). Also, Gβγ and
can activate inward rectifying K+ channels and inhibit voltage-dependent calcium
channels (104). CB2 activity is increasingly complicated by the biased signaling
demonstrated by different agonists to the CB2 receptor. Active states of the CB2 receptor
stabilized by different ligands exposes serines and threonines that can be phosphorylated
by G protein-coupled receptor kinases leading to β-arrestin recruitment (100). Arrestins
are a family of proteins involved in GPCR desensitization and internalization and there
are two two isoforms that interact with CB2, β-arrestin 1 and β-arrestin 2 (101, 104, 105).
The CB2 receptor can interact with both β-arrestin isoforms. However, these isoforms are
differentially expressed and show different levels specificity in various cell types and for
specific GPCRs (106). Recently it has been demonstrated that CB2 internalization occurs
through interaction with β-arrestin 2 resulting in rapid recruitment to endocytic pits where
CB2 and colocalizes with β-arrestin 1 at endosomes resulting in β-arrestin 1 recruitment
and signaling (107). The current knowledge regarding arrestin mediated signaling
suggests GPCRs activated by different ligands produce different receptor confirmations
depending on the type of ligand and where it binds resulting in differential downstream
effects (108). These different ligand-dependent GPCR confirmations can act through
either G-protein signaling or β-arrestin dependent signaling, a phenomenon known as
functional selectivity or biased signaling opening a new avenue to utilize various CB2
functionally specific agonists therapeutically following future investigations into the
effects of these compounds in multiple models of renal disease. For example, Hu-308 and
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JWH-133, two commonly used CB2 agonists, display very different bias toward different
effector pathways. While both HU-308 and JWH-133 activate CB2 with a high level of
specificity in the mouse, HU-308 has the ability to activate GIRK channels while JWH133 does not (100). This seemingly minor difference between the two compounds can
cause vastly different physiological outcomes.
In conclusion the kidney is an organ of great importance in the maintenance of
homeostasis and can be damaged by a variety of insults leading to AKI. To date there is
no therapeutic available to ensure improved recovery from AKI. Recent studies have
demonstrated the potential of CB2 as an emerging therapy in AKI. The following studies
will highlight the progress by our group in uncovering the effects of CB2 activation in
AKI by a novel selective CB2 agonist SMM-295.
Specific Aims
In the United States acute kidney injury (AKI) is responsible for more than $10
billion in economic costs annually. The prevalence of AKI is increasing with an overall
incidence of 22% globally in adult patients and is associated with further renal
complications, including chronic kidney disease (CKD) and end stage renal disease, as
well as cardiovascular disease and stroke.
A critical barrier is the lack of established therapeutics available to treat patients
following AKI. Cannabinoid signaling has been implicated in renal disease and may
provide a therapeutic target for the treatment of AKI. Recent studies have shown a
protective effect of CB2 activation in chronic and acute models of kidney disease. To
address the need for increased selective CB2 agonists our group has developed a novel
CB2 agonist, SMM-295.
My goal in this proposal is to further categorize the effects of CB2 activation by
SMM-295 in IRI and provide evidence for effective therapeutic strategies for the
treatment of the disease which are currently lacking. This goal will function to uncover
potential mechanisms through which CB2 activation contributes to renal tissue protection
in response to IRI and build upon the current knowledge surrounding cannabinoid
signaling in AKI which has direct implications for other chronic end of life diseases.
Therefore, my hypothesis for this proposal is that novel CB2 agonist SMM-295
has a favorable PK/PD profile and ameliorate acute kidney injury through both antiapoptotic effects on proximal tubule cells and vasodilatory effects on renal vascular cells
leading to increased renal function and recovery from AKI. The following aims have
been designed to test this hypothesis:
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Aim 1: Determine the Effects of Novel Cannabinergic Drugs in a Mouse Model of
IRI
Recent studies have suggested a beneficial role of cannabinergic drugs regarding
both acute and chronic kidney disease. While these studies have looked at specific
agonists to CB1 and CB2 our study is the first to compare different types of CB1 and
CB2 agonists and inverse agonists side-by-side to determine their effectiveness in
treating IRI. It is our hypothesis that CB2 receptor agonists will cause decreases in renal
damage and increases in renal function and CB1 agonists and CB2 inverse agonists
resulting in the opposite effects in the immediate aftermath of IRI in mice.
Aim 2: Categorize and Determine the Therapeutic Potential of SMM-295 in
Treatment of IRI
The hypothesis of this aim is that SMM-295 activation of CB2 receptors has a
beneficial effect on recovery from IRI, in part due to protection of proximal tubule cells
from cell death. Therefore, the function of this aim is to determine whether SMM-295 has
therapeutic protentional when administered following IRI. Our data suggests mRNA
levels of cnr2 increase following IRI in kidney lysates indicating a role of CB2 in
recovery from the disease. This aim will describe the effects of CB2 activation on renal
clearance, morphology, and tubular cell apoptosis levels following IRI.
Aim 3: Determine the Renal Hemodynamic Effects of CB2 Receptor Agonist SMM295
This aim will determine the mechanisms responsible for decreased vascular
reactivity and increased renal blood flow seen with the administration of CB2 agonists.
The hypothesis for this aim is that CB2 receptor activation will lead to increased blood
flow to the kidney and aid in the recovery from IRI. To achieve this goal, we will employ
a mixture of in vitro, ex vivo, and in vivo techniques to further describe the signaling
cascades responsible for the decrease in vascular reactivity following CB2 activation in
our preliminary studies.
My expected outcomes and impact will be: 1) outline the effects of cannabinergic
drugs in IRI, 2) determine a beneficial effect of CB2 activation following IRI and 3)
uncover the mechanisms surrounding CB2 activation and renal hemodynamics. These
studies will provide fundamental pre-clinical information that is necessary in the
development of novel therapeutic approaches to AKI, a debilitating disease with lacking
therapeutic strategies.
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CHAPTER 2.

EFFECTS OF NOVEL CANNABINERGIC DRUGS IN A MOUSE
MODEL OF IRI1
Introduction

Over the last decade, the commercial availability of synthetic cannabinoid
targeting compounds has increased rapidly, with varying degrees of specificity and
efficacy (109). While a plethora of these compounds exists, each has its own set of
pharmacokinetic and pharmacodynamic properties that make them individually distinct
with regards to their modality (109). Due to the overlap of structural similarities between
CB1 and CB2 structure, many drugs aimed at one of these receptors may have some
activity at both (110). Initial studies determining the effects of drugs acting on the
cannabinoid system following AKI demonstrate interesting results. Feizi et al. (76)
showed a dose-dependent reduction in tubular damage following IRI with the
administration of both selective CB1 and CB2 receptor agonists,
arachidonylcyclopropylamide and JWH-133 respectively. These data highlight the early
confusion surrounding the role of CB1 and CB2 in the kidney to treat AKI.
More recently, there is a trend showing that there is a beneficial role of
cannabinergic compounds by either blocking CB1 or activating CB2 in animal models of
both acute and chronic kidney disease (76-82). For example, new selective CB2 agonists
results in reduced markers of renal injury following ischemia-reperfusion injury (76).
This data coincided with other studies that showed a beneficial effect in the recovery
from cisplatin-induced renal injury of CB2 agonists, LEI-101 and HU-308(80, 82).
Confirming these effects is another study where β-caryophyllene, a natural CB2 agonist,
also was protected the tubular epithelial cells from cisplatin-induced renal injury (79).
While the cisplatin-induced renal injury is dependent on dose and is more likely to get
consistent results across labs, IRI conditions can vary between research groups which are
influenced by factors including surgical environment, duration of ischemic injury, and
recovery conditions (111). Thus, data determining the effects of cannabinoids in the
recovery from IRI between relatively few isolated groups that are performing these
experiments are increasingly challenging to compare. Therefore, there is a need to
perform a comprehensive screen including agonists and inverse agonists at CB1 and CB2
to systematically determine the therapeutic contribution in the context of AKI.
To understand the role of CB1 and CB2 activity following IRI, we performed a
blinded screen of 4 distinct CB1/CB2 agonists and inverse agonists (Table 2-1),

1
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H., Alghamdi, S., Pandey, P., Roy, K. K., & Park, F. (2018). Selective cannabinoid 2 receptor stimulation
reduces tubular epithelial cell damage after renal ischemia-reperfusion injury. Journal of Pharmacology
and Experimental Therapeutics, 364(2), 287-299. https://doi.org/10.1124/jpet.117.245522 Final submission
copy used. (93).

13

Table 2-1.

Cannabinergic compounds

Drug Name
SMM-295
SMM-189
KM-233

Mode of Action
CB2 agonist
CB2 inverse agonist
CB1 agonist and CB2
neutral antagonist

SR-141716A
JWH-133

CB1 inverse agonist
CB2 agonist
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Reference
(93)
(112)
Relayed by personal
communication with Dr.
Bob Moore
(114)
(113)

SMM-295 (93), SMM-189 (112), KM-133,JWH-133 (113) and S141716A (114) using a
mouse model of bilateral IRI. Bilateral IRI was our preferred mouse model of AKI rather
than unilateral IRI, because unilateral IRI has a contralateral kidney that remains
undamaged and can functionally compensate for the other injured kidney. Therefore,
changes in AKI indicators, creatinine and NGAL, can be partially masked by the
undamaged contralateral kidney. with regards to recovery of the kidney from IRI. We
believe that this set of experiments will provide us new information on the direction of
future studies using CB compounds to promote therapeutic responses in the kidney
following AKI.
Materials and Methods
Cannabinergic Compounds
Table 2-1 lists the cannabinergic compounds used in this study.
Renal Bilateral Ischemia-Reperfusion Injury
C57Bl/6 mice (6-7 weeks of age) were obtained from Jackson Laboratories and
allowed to acclimate for at least three days before performing bilateral renal IRI
surgeries. All protocols are approved by the Institutional Animal Care and Use
Committee (IACUC) at the University of Tennessee Health Science Center, Memphis.
All mice were provided ad libitum access to mouse chow and water before and after the
surgical procedures. Mice were anesthetized with pentobarbital (50-80 mg/kg IP), and
renal flank incisions were made on each side of the mice to isolate the kidneys for
clamping of the renal hilus using microisolator clamps. After clamping the organs, they
were placed back into the abdominal area, and body temperature was maintained between
35-37oC as monitored by a rectal temperature probe. At the end of 24.5 minutes, the
clamps were removed and immediately administered vehicle, SMM-189 (6 mg/kg IP),
SMM-295 (6 mg/kg IP), SR141716A (6 mg/kg IP), or KM-133 (6 mg/kg IP) (Table 2-1).
The kidneys were subsequently monitored for the restoration of blood perfusion by the
kidneys before the closure of the wounds. All mice were administered analgesics and
antibiotics following the surgery, and if needed during the remainder of the experimental
period. After 24 hours, another dose of vehicle, SMM-189 (6 mg/kg IP), SMM-295, (6
mg/kg IP), SR141716A (6 mg/kg IP), or KM-133 (6 mg/kg IP) was administered to each
of the mice. Body weights were also obtained during the experimental period. The mice
were euthanized after either 24 or 48 hours, and the kidneys were harvested for fixation
in neutral buffer formalin to perform histology.
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Serum Markers of Renal Injury
Blood samples were collected in citrate-coated tubes after 24 and 48 hours
following renal ischemia-reperfusion injury, and plasma was isolated by differential
centrifugation. Creatinine levels were measured by LC-MS/MS (Department of
Biochemistry, the University of Alabama at Birmingham, AL). NGAL was measured by
ELISA (cat #89189, Abcam).
Histological Analysis of the Kidney
Formalin-fixed, paraffin-embedded kidneys were sectioned (4 Pm thick), deparaffinized using xylene, dehydrated using increasing concentrations of ethanol, and
stained with H&E. Tubular damage was determined as a percent of the total tubules by
using images at 40X magnification using previously published criteria (115, 116).
Statistical Analysis
All values are shown as mean +/- SEM using GraphPad Prism 6.0 software.
Either unpaired t-test or one-way ANOVA was performed using Bonferroni’s post-hoc
test to confirm significant differences (P<0.05) between animal groups.
Results
CB2 Receptor Activation Reduced Renal Injury Following Renal Bilateral
Ischemia-Reperfusion Injury
Following renal bilateral IRI, either SMM-295 (6 mg/kg IP; n=5), KM-133 (6
mg/kg IP; n=4), SR141716A (6 mg/kg IP; n=4), SMM-189 (6 mg/kg IP; n=4), or vehicle
solution (n=6) was administered immediately upon removal of the renal clips, and blood
was harvested to measure plasma creatinine levels, a functional marker of renal injury,
after 24 hours. Creatinine levels were significantly lower (P=0.001) in mice treated with
SMM-295 (0.3 ± 0.1 mg/dL) compared to the vehicle solution control mice (1.3 ± 0.2
mg/dL) (Figure 2-1). Mice treated with CB2 inverse agonist, SMM-189 (2.0 ± 0.5
mg/dL), CB1 agonist, KM-233 (1.3 ± 0.2 mg/dL), and CB1 inverse agonist, SR141716A
(1.7 ± 0.2 mg/dL) did not show a significant change (P>0.05) in creatinine levels
compared to vehicle-treated mice (Figure 2-1).
After 48 hours of reperfusion following the ischemic period, treatment with
SMM-295 caused significant (P=0.0002) reduction in outer medullary tubular epithelial
cell damage by ~33% (35.7 ± 2.2% damaged tubules; n=4; Figure 2-2B, F) compared to
vehicle-treatment (62.0 ± 2.2% damaged tubules; n=4; Figure 2-2A, F). Mice treated
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Figure 2-1. Serum analysis from mice following bilateral ischemia-reperfusion
injury in the presence or absence of CB2 activation
Plasma measurements were obtained for (A) creatinine in IRI-treated mice administered
either SMM-295 (6 mg/kg IP; n=5), KM-133 (6 mg/kg IP; n=4), SR141716A (6 mg/kg
IP; n=4), SMM-189 (6 mg/kg IP; n=4), or vehicle solution (n=6) after 24 hours. * P<0.05
significant difference between groups.
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Figure 2-2. Tissue analysis from mice following bilateral ischemia-reperfusion
injury in the presence or absence of CB2 activation
(A-E) displayed are representative images from IRI-treated mouse kidneys administered
either with (A) vehicle solution (n=6), (B) SMM-295 (6 mg/kg IP; n=4), (C) SMM-189
(6 mg/kg IP; n=4), (D) KM-133 (6 mg/kg IP; n=4), or (E) SR141716A (6 mg/kg IP; n=4)
after 48 hours. Scale bar = 100 μm. * indicate cast-containing tubules (F) Tubular
damage is graphed as a percentage of the total number of tubules from the outer
medullary. * P<0.05 significant difference between groups.
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with CB2 inverse agonist, SMM-189 (83.4 ± 5.7% damaged tubules; n=4; Figure 2-2C),
CB1 agonist, KM-233 (79.3 ± 5.4% damaged tubules; n=4; Figure 2-2D), and CB1
inverse agonist, SR141716A (65.0 ± 6.9% damaged tubules; n=4; Figure 2-2E) did not
show a significant change (P>0.05) in tubular damage levels compared to vehicle-treated
mice. Similarly, significantly lower NGAL levels (P=0.015) were measured in the blood
from mice treated with SMM-295 (4,489 ± 680.5 ng/mL) compared to vehicle (11,252 ±
1,867 ng/mL) (Figure 2-3B).
Effects of Novel CB2 Agonist, SMM-295, Compared to the “Gold Standard”
Commercially Available CB2 Agonist, JWH-133
Novel CB2 agonist, SMM-295, and commercially available CB2 agonist, JWH133, both provide protection from renal damage following IRI. Both SMM-295 and
JWH-133 led to a statistically significant decrease in tubular damage, 26.39% ± 12.81%
(P=0.0002; n=4) and 17.34% ± 13.83% (P=0.02; n=3) respectively, compared to vehicletreated mice (n=4) (Figure 2-3C). However, SMM-295 (n=5) shows significantly
decreased levels of creatinine (P=0.001) and NGAL (P=0.015) compared to vehicletreated mice, while JWH-133 (n=7) failed to significantly decrease (P>0.05) these levels
compared to vehicle-treated mice (n=6) (Figure 2-3A, B) suggesting a possible
additional functional benefit of SMM-295 in the recovery from IRI.
Discussion
These results demonstrate that CB2 activation by SMM-295 can prevent renal
injury following AKI while we also show that CB1 agonist, and inverse agonist, KM133, and CB1 inverse agonist, SR141716A respectively, failed to engender a statistically
significant change in plasma creatine levels or tubular damage following IRI. These
findings clarify the actions, particularly differences between CB1 and CB2 activation, of
the cannabinoid system activation in IRI and provide additional measures of renal
damage to confirm previously done studies in the literature. Recently, clinical cases are
demonstrating that exogenous cannabinoids acting on CB1 receptor can also lead to a
disruption in normal renal function resulting in AKI (117, 118). The mechanism by
which renal function is impaired by cannabinoid signaling remains to be determined but
may involve the differential activation of the CB1 and CB2 receptors (83, 85, 86). While
the contributions of CB1 versus CB2 activation in regard to AKI have not been fully
established, data from the field of CKD may provide some insight as to the potential roles
in AKI. In CKD, CB1 receptor activation aggravates glomerular and tubular epithelial
cell damage to exacerbate decrements in renal function (89), but in many cases,
activation of the CB2 receptor can counteract the harmful effects mediated by the CB1
receptor (84, 119, 120).
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Figure 2-3. Comparison of novel CB2 agonist, SMM-295, compared to the “gold
standard” CB2 agonist, JWH-133
Commercially available CB2 agonist, JWH-133, and novel CB2 agonist, SMM-295,
leads to decreased tubular damage following IRI (A). However, SMM-295 leads to
decreases in creatinine and NGAL levels (B,C) whereas JWH-133 doesn’t show this
effect as creatinine and NGAL levels in JWH-133 treated mice are statistically similar as
mice treated with vehicle.
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In obesity-related nephropathy, activation of the CB2 receptor with AM-1241
reduced urinary protein excretion and attenuated the appearance of fibrotic markers
(120). This effect is confounded by the low specificity of AM-1241 between the CB1
and CB2, showing 71% activity at the CB1 receptors, along with off target effects at
other receptors outside the cannabinoid system like 5HT (100).
Similarly, chronic renal function was improved in the presence of selective CB2
activation using either an experimental or genetic mouse model of diabetes (84, 121).
Urinary albuminuria and podocytes protein loss were dramatically reduced in the AM1241 treated mice compared to the vehicle group (121). Consistent with these results,
reduced glomerular damage was observed in the BTBRob/ob leptin-deficient mouse model
of progressive diabetic nephropathy following administration of another CB2 agonist,
HU-910 (84). Although the exact mechanism by which the renal architecture and
function were preserved is not fully described, it may involve CB2 receptor-dependent
inhibition of the immune system (120). Diabetic nephropathy is associated with
increased chemokine production, inflammatory cell infiltration, and the consequent
release of ROS and inflammatory mediators that activate tubular cell apoptosis (82). The
CB2 receptor has been demonstrated to be highly produced in immune cells (122, 123),
which is a necessary cell type that is recruited to the kidney upon the presentation of a
damage response by injured tubular epithelial cells, especially during diabetic
nephropathy (82). Glomerular damage was lessened by the decreased accumulation of
monocytes and macrophages in the presence of HU-910, a CB2 agonist (84). Chronic
treatment with CB2 receptor agonist, HU-308 limits inflammatory signaling by reducing
oxidative stress, which can help to attenuate the nephropathic injury by possibly
preventing tubular cell apoptosis (82, 121).
The precise nature of the role of the cannabinoid receptors in the kidney during
AKI remains to be fully understood. Cannabidiol, a modest CB2 inverse agonist and
weak CB1 antagonist (124), was shown to have a beneficial effect on renal function
following IRI (77). In this study, the specific receptor activation was not evaluated, but
the protection of the kidney was associated with reduced expression of pro-inflammatory
factors (77). In another study using a rodent model of renal IRI, tubular epithelial cell
damage was prevented following dose-dependent administration of either CB1 or CB2
receptor agonists (76).
This study provided us with some clarity regarding the role of cannabinoids in
AKI by determining the effects on renal damage and function across a comprehensive
profile of cannabinergic drugs. This pilot study suggests that CB2 activation has
beneficial effects in the recovery of IRI creating possibilities for novel therapeutics
clinically approved for the treatment of AKI. Furthermore, our novel CB2 agonist SMM295 led to a consistent improvement in all aspects of AKI from serum markers to
histological damage compared to another commercially available “gold standard” CB2
agonist, JWH-133, which tended to show renal improvement in some, but not all
parameters. JWH-133 is known in the mouse to favor GTPase activity over cAMP and
β-Arresting signaling moieties and displays no GIRK activity (100). It is not clear as to
the reason for the lack of consistency across all of the assays for JWH-133 compared to
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SMM-295, but it is most likely related to the ability of the ligand to differential stabilize
distinct CB2 active states leading to functionally selective activation of downstream
pathways, the need for higher doses for JWH-133, or activation of other non-CB2
receptors that helped to promote the beneficial effects. Regardless, both of these
compounds provide us with the confidence that the CB2 can provide renal protection
following exposure to AKI stimuli.
The mechanism by which CB2 activation leads to decreases in renal damage and
increases in renal function early in the recovery from IRI has yet to be described. The
pathways responsible for this protection could include a direct (or indirect) effects on the
tubular epithelial cells, and possibly a change in the renal hemodynamics in response to
CB2 agonism. Studies in the heart suggest that CB2 activation leads to activation of prosurvival pathways in ischemic injury (125). It has yet to be determined if this effect
translates to the kidneys and more specifically tubular epithelial cells. If there is indeed
activation of pro-survival pathways in tubular epithelial cells following CB2 activation
this would explain the preservation of tubular structure in SMM-295 treated mice
following IRI. Furthermore, CB2 activation leads to changes in systemic hemodynamics
and has effects on blood pressure and vascular resistance (126-128). However, the
implications of CB2 activation in regard to renal hemodynamics has not been studied in
depth. In the following chapters, the mechanisms through which SMM-295 leads to
decreases in renal injury and increases in renal function will be investigated in the early
stages of recovery from IRI.
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CHAPTER 3.

CHARACTERIZATION OF CB2 AGONIST SMM-295 AND ITS
EFFECTS IN IRI.2
Introduction

Acute kidney injury (AKI) has clinically become an increasing problem for
patients of all ages that has been linked with an elevated risk of mortality (129, 130).
Most of the patients that develop AKI are in a pre-renal state, which typically includes
organ hypoperfusion associated with sepsis, fluid depletion, pharmacological reductions
in blood pressure, and vessel occlusion (6, 131). AKI is an important risk factor in the
progression towards chronic kidney disease, which can also be a reciprocal risk factor in
potentiating the onset of AKI (132, 133). At present, there remains a lack of adequate
therapeutic approaches to diagnose and subsequently treat patients following an episode
of AKI. Even though there is an increasing knowledge base regarding the mechanisms
involved in the onset and recovery of damaged renal cells, particularly tubular epithelial
cells (2, 6, 134), further investigations are clearly in need to expand upon the current state
of mechanistic understanding and have the possibility to increase our ability to develop
new therapeutic targets.
The role of the cannabinoid system in the kidney following activation of its
cognate G-protein coupled receptors, CB1 and CB2, is continuing to emerge as a crucial
response system following injury stimuli to the kidney. CB1 and CB2 activation can
exert a diverse array of biological functions, due to a combination of factors, which
includes their ability to interact with several heterotrimeric G-protein α subunits,
including Gαi, Gαs and Gαq/11 (135), and their distribution within the distinct cell types
in the kidney. The CB1 receptors are expressed in high abundance with a fairly broad
localization pattern, which includes all segments of the nephron and vasculature (135).
On the other hand, the CB2 receptor has been primarily detected in the renal cortex,
specifically in mesangial cells and podocytes in the glomerulus (92, 119), and proximal
tubular epithelial cells (87, 136, 137). Selective activation of CB2 receptor has been
shown to be protective of renal architecture and nephron function by mitigating the
nephropathic effects associated with diabetes (82, 84) or diet-induced obesity (137) in
rodent models of chronic kidney injury. Diabetic nephropathy was attenuated following
treatment with a natural CB2 agonist BCP (79), or a small molecule analog functioning
as a CB2 agonist (82). Similarly, CB2 receptor activation in rodents with diet-induced
obesity ameliorated their progression towards renal dysfunction as determined by urinary
protein and sodium excretion rates (137). Conversely, CB2 receptor antagonists reduced
renal function as measured by creatinine clearance, which suggests that renal failure was
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exacerbated (137). These data demonstrate the potential clinical benefit of CB2 receptor
agonists to treat chronic forms of kidney injury, but further investigations are needed to
determine the utility of harnessing the CB2 receptor system following acute kidney
injury.
Towards addressing this issue, Chapter 2 described our unbiased approach to
identify modulators of the CB2 receptor of which a small molecule agonist, SMM-295,
was identified to exert a therapeutic effect on reducing tubular epithelial cell damage
following renal IRI. This chapter will describe new experiments that further categorize
our novel CB2 agonist, SMM-295, in pharmacokinetic studies in vivo and in vivo as well
as a more expansive study to determine its therapeutic potential to prevent tubular
epithelial cell damage using a mouse model of renal bilateral IRI, which is a common
type of AKI. The findings in our study will demonstrate that further investigation into
selective activation of the CB2 receptor is merited to elucidate its potential as a therapy to
treat AKI.
Materials and Methods
Reagents
G418 was purchased from KSE Scientific (Durham, NC). Puromycin, DMEM,
penicillin/streptomycin, gentamicin, DPBS, Hank’s Buffer, HEPES, EDTA, Tris base,
sucrose, MgCl2, Millipore filter plates and punch kits, Eco-Lite scintillation cocktail, and
Poly-D-lysine coated 96-well plates were purchased from Fisher Scientific (Waltham,
MA). Ambisome and FBS were purchased from Atlanta Biologicals (Flowery Branch,
GA). Ro 20-1724, acetonitrile, DMSO, lipopolysaccharide (LPS), polyethyleneamine,
and fatty acid-free BSA were purchased from Sigma Aldrich (St. Louis, MO). Antibodies
against proliferating cell nuclear antigen (PCNA) was purchased from Cell Signal. High
bind plates (L15XB-3), anti-rat (R32AA-5), and anti-rabbit (R32AB-1) SULFO-TAG
antibodies were purchased from Meso-Scale Discovery (Gaithersburg, MD). ACTOne
Membrane Potential Dye was purchased from Codex BioSolutions (Gaithersburg, MD).
Forskolin was purchased from Tocris (Bristol, UK).
Receptor Binding
Membrane proteins were isolated using binding buffer, as previously described
(138). Prior to starting the assay, filter plates were prepared by incubating with 0.05%
(w/v) polyethyleneamine mixed in deionized water for 60 minutes at room temperature.
Afterwards, plates were filtered and washed 5 additional times with deionized water
using a vacuum manifold. In each well, 10 μg of membrane protein was added in the
presence of [3H]-CP 55,940 (final concentration 1 nM) with or without test ligands, such
as SMM-295 (concentration range from 1 nM to 10 μM). The samples were incubated at
30°C for 90 minutes, and then washed up to 9 times using binding buffer. At end of the
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final wash, the plate backing was removed, vacuum dried, and individual filters were
collected using punch tips into scintillation vials containing Eco-Lite scintillation solution
(5 mL). Vials were incubated overnight and analyzed the following day using the
PerkinElmer Liquid Scintillation Analyzer Tri-Carb 2810TR with a dwell time of 3
minutes. All binding studies were performed with a minimum of 6 biological replicates,
and the following parameters were measured: CB1 Kd was 1.98 ± 0.6 nM, Bmax 8.47 ±
2.35 pmol/mg. CB2 Kd was 1.65 ± 0.5 nM, Bmax 3.18 ± 0.1 pmol/mg.
ACTOne Functional Assay
HEK-CNG, HEK-CNG+CB1, and HEK-CNG+CB2 cells were obtained from
Codex BioSolutions (Gaithersburg, MD). The ACTOne functional assay was performed
as described by Presley et al. (139). In brief, 5 x 104 cells were plated into clear poly-Dlysine coated 96-well plates using DMEM containing 10% FBS and 1%
penicillin/streptomycin. The following day, SMM-295 or CP 55,940 was evaluated at
final concentrations from 5 x 10 PM down to 500 x 10 pM in the presence of either or
both Ro 20-1724 (25 μM) and forskolin (0.8 μM) in DPBS with 2.5% (v/v) DMSO. At
this point, the plates were read using a BioTek (Winooski, VT) plate reader (Ex 540 nm,
Em 590 nm) at 50 mins. At least six biological replicates were performed for each data
set.
Drug Permeability Assay
Bidirectional drug permeability for SMM-295 (5 μM) was tested using the Caco-2
human epithelial cell line as previously described (140). As a positive control for Pglycoprotein (P-gp) efflux, loperamide (5 μM) was used in the assay. Verapamil (100
μM) was used as an inhibitor for P-gp transport activity. All data are shown as 10−6 cm/s.
Plasma Protein Binding by SMM-295
Rapid equilibrium dialysis (RED) was performed using a commercial plate-based
RED device. SMM-295 was diluted to a final concentration of 5 μM in triplicate using
mouse and human plasma. As a control, warfarin was diluted to 5 μM using mouse and
human plasma, and PBS (pH 7.4) was added to the buffer chamber. After the RED device
was sealed with an adhesive film, dialysis was performed in an incubator at 37°C with
shaking at 100 rpm for 4 hours. Aliquots of the buffer and the plasma were measured at
specific times with a calibration curve by LC-MS/MS to determine the concentration of
free and bound test compound by LC-MS/MS analysis. The calculation of the peak area
ratios between the analyte versus the internal standard was used to determine the fraction
of compound bound to plasma proteins.
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Cytochrome P450 Metabolism Assay
The in vivo stability of SMM-295 was assessed in duplicate using purified
cytochrome P450 (P450) enzymes and measuring the disappearance of the native
compound over an incubation period of 60 minutes. The various P450 proteins (50
pmol/ml) and their positive control drugs (in parentheses; 1 μM) tested in our assay are as
follows: CYP1A2 (phenacetin), CYP3A4 (terfenadine), CYP2C9 (diclofenac), CYP2C19
(lansoprazole), and CYP2D6 (propranolol). SMM-295 (1 μM) was added to each of the
P450 enzymes, and the samples were placed in a 96-well plate that was preincubated at
37°C. NADPH was added to a final concentration of 1 mM to initiate the reaction, and all
reactions were terminated using ice-cold acetonitrile containing an internal standard at 0,
5, 15, 30, and 60 minutes. The plates were centrifuged at 4000 rpm for 15 minutes, and
an aliquot from each sample was analyzed by LC-MS/MS to determine the percentage
change in the native versus metabolized compounds and the calculation of the compound
half-life.
Human Ether-a-Go-Go–Related Gene Assay
The potential inhibitory effect by SMM-295 (1 and 10 μM) on the human Ether-aGo-Go–related gene (hERG) channel was evaluated using the predictor hERG
fluorescence polarization assay kit as per the manufacturer’s instructions (Life
Technologies, Carlsbad, CA).
In Vivo Pharmacokinetic Studies
Animal studies were performed by SAI Life Sciences Ltd. (Hyderabad, India)
using an institutional animal ethics committee protocol (number FB-15-103). Twentyseven male C57BL/6J mice (aged 8–12 weeks; 25–35 g) were obtained from ACTREC
(Maharashtra, India) and maintained in a temperature- and humidity-controlled
environment under 12-hour light/dark cycles. All mice were allowed ad libitum access to
food (Envigo Research Private Ltd., Hyderabad, India) and water.
The mice were administered SMM-295 (6 mg/kg i.p.), which was formulated in
5% (v/v) 200-proof ethanol, 5% (v/v) Cremophor ELP (BASF, Germany), and 90%
normal saline. At each time point (0.08, 0.25, 0.5, 1, 2, 4, 8, 12, and 24 hours), three mice
were euthanized to collect blood and kidney samples for measurement of SMM-295.
Plasma was isolated from the collected blood by centrifugation, and the kidneys were
immediately homogenized using ice-cold PBS (pH 7.4). The plasma and kidney
homogenates were stored at −70°C until analysis by fit-for-purpose validation by LCMS/MS to obtain the concentration–time data for SMM-295. Subsequently, the plasma
concentration–time data were used to calculate other pharmacokinetic variables using the
noncompartmental analysis module in Phoenix WinNonlin software (version 6.3; Certara,
Princeton, NJ). Maximum concentration (Cmax) and time to reach the maximum
concentration (tmax) were the observed values. The areas under the concentration–time
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curve (AUClast and AUCinf) were calculated using the linear trapezoidal rule. The
terminal elimination rate constant (ke) was determined by regression analysis of the linear
terminal portion of the log plasma concentration–time curve.
Renal Bilateral Ischemia-Reperfusion Injury
C57Bl/6 mice (6-7 weeks of age) were obtained from Jackson Laboratories and
allowed to acclimate for at least three days before performing bilateral renal IRI
surgeries. All protocols are approved by the Institutional Animal Care and Use
Committee (IACUC) at the University of Tennessee Health Science Center, Memphis.
All mice were provided ad libitum access to mouse chow and water before and after the
surgical procedures. Mice were anesthetized with pentobarbital (50-80 mg/kg IP), and
renal flank incisions were made on each side of the mice to isolate the kidneys for
clamping of the renal hilus using microisolator clamps. After clamping the organs, they
were placed back into the abdominal area, and body temperature was maintained between
35-37oC as monitored by a rectal temperature probe. At the end of 24.5 minutes, the
clamps were removed and immediately administered vehicle, SMM-189 (6 mg/kg IP),
SMM-295 (6 mg/kg IP), SR141716A (6 mg/kg IP), or KM-133 (6 mg/kg IP) (Table 2-1).
The kidneys were subsequently monitored for the restoration of blood perfusion by the
kidneys before the closure of the wounds. All mice were administered analgesics and
antibiotics following the surgery, and if needed during the remainder of the experimental
period. After 24 hours, another dose of vehicle or SMM-295 (6 mg/kg IP) was
administered to each of the mice. Body weights were also obtained during the
experimental period. The mice were euthanized after either 24 or 48 hours, and the
kidneys were made into lysates for immunoblot analysis.
LC-MS/MS Assay of SMM-295
Plasma and kidney homogenates in ice-cold PBS (pH 7.4) were isolated by
centrifugation, and protein extraction was achieved using a 4:1 (acetonitrile/sample) ratio.
As an internal control, glipizide (500 ng/ml) was added to each sample except for the
blank control. Samples were vortexed and centrifuged for 10 minutes at 4000 rpm at 4°C.
After centrifugation, 100 μl clear supernatant was transferred in 96-well plates and
analyzed using LC-MS/MS. Chromatographic separation was achieved using a Kinetex
EVO C18 column (3 μm, 100 × 4.6 mm i.d.; (Phenomenex, Torrance, CA). The system
delivered a constant flow of 1 ml/min, with the mobile phase consisting of 0.1% formic
acid in acetonitrile and 10 mM ammonium formate injected at a volume of 5 μl at a
temperature of 45°C. Detection of SMM-295 and standards was performed with the
QTRAP 4000 LC/triple-quadruple mass spectrometer (SCIEX, Concord, ON, Canada). A
calibration curve was constructed and validated with spiked samples in either plasma or
kidney homogenates.
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Reverse Transcription Polymerase Chain Reaction Analysis for CB2 Receptor
mRNA
Total RNA was extracted from IRI-treated and contralateral kidneys using TRIzol
reagent as previously described in our laboratory (141). DNAse treatment was performed
on the total RNA, and the RNA was re-extracted with TRIzol reagent. Reverse
transcription was performed using SuperScript III reverse transcription kit (Life
Technologies). Upon completion of the reverse transcription step, polymerase chain
reaction was performed using specific TaqMan primers targeted to the Cnr2 and 18s
cDNA. Polymerase chain reaction product formation was calculated by the delta delta Ct
(ΔΔCT) method, as previously performed by our laboratory (141). The resulting fold
change of Cnr2 mRNA is the difference between the injured and uninjured kidneys
normalized to 18s mRNA to control for variation between samples.
Hypoxia/Reoxygenation Injury in NRK-52E Cells
Protein lysates were isolated from normal rat kidney NRK-52E cells treated with
SMM-295 (1, 2, and 10 mM) for 15 minutes using established protocols in our laboratory
(115, 116, 142, 143). In addition, NRK-52E cells were incubated for 12 hours in an
incubator containing 4% oxygen and 5% carbon dioxide. After the hypoxic period, the
cells were incubated in normal oxygen conditions in media containing either 2 μM SMM295 or an equal volume of vehicle (DMSO) for 3 hours and lysates were collected for
Western blot analysis.
Immunoblot Analysis
Protein samples were loaded onto a 4%–20% gradient SDS‐PAGE gel for size
fractionation, transferred onto a PVDF membrane, and incubated with primary antibodies
(phospho- and total Akt; catalog numbers 9721 and 9272), extracellular signal–regulated
kinase 1/2 (catalog numbers 8101 and 9102), p38 mitogen-activated protein kinase
(MAPK) (catalog numbers 9211 and ab31828; Abcam), Bcl-xL (catalog number 2764),
cleaved caspase 3 (CC3; catalog number 9665), and Bcl-2 (catalog number 2870) from
Cell Signaling Technologies, unless otherwise mentioned, at a 1:1000 dilution overnight
in 4°C conditions. Secondary goat anti‐rabbit or anti-mouse horseradish peroxidase–
linked IgG (1:1500 dilution; Cell Signaling Technologies; catalog numbers 7074 and
7076) secondary antibody was used for detection by chemiluminescence. Membranes
were scanned using the Bio-Rad chemiluminescent detection system (Bio-Rad, Hercules,
CA), and band intensities were calculated by ImageJ software (National Institutes of
Health, Bethesda, MD). β‐actin (1:8000, catalog number MA515739HRP; Thermo Fisher
Scientific) was used as the loading control, and the relative expression of protein levels
was calculated by normalizing band intensity values of the proteins of interest to either
one of the loading controls.
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Statistical Analysis
The data and statistical analysis comply with the recommendations on
experimental design and analysis in pharmacology (144). All values are shown as means
± S.E.M. using GraphPad Prism software (version 6.0; GraphPad Inc., La Jolla, CA).
Either an unpaired t test or one-way analysis of variance was performed using StudentNewman-Keuls post hoc analysis to confirm significant differences (P < 0.05) between
animal groups. Post hoc testing was only performed if F achieved P < 0.05 and there was
no significant variance in homogeneity. For the ACTOne data, nonlinear analysis was
performed.
Results
Physicochemical and Pharmacokinetic Properties of SMM-295
The chemical structure of SMM-295 is shown in Figure 1A Following
intraperitoneal injection of SMM-295, the maximal plasma concentration (Cmax, plasma)
was 304.4 ± 40.3 ng/mL after 0.25 hour (tmax, plasma) (Figure 3-1B). In the kidney, there
was high concentration of SMM-295 after 0.08 hour (tmax, kidney) with an average peak
value of 9,826 ± 5,461 ng/g kidney tissue (Cmax, kidney) (Figure 3-1C). Using these
values, the half-life (t1/2) of SMM-295 was calculated at 0.25 hour and could be detected
in the plasma between 4 to 8 hours. SMM-295 was highly bound to plasma proteins in
both mouse and humans at >99%. The high plasma binding was similar to warfarin,
which was used as a positive control since it binds to human (98.8 ± 0.2%) and mouse
(96.9 ± 0.2%) proteins (Table 3-1).
Bidirectional permeability of SMM-295 using the standard Caco-2 cell system
demonstrated that SMM-295 was moderately transported through the cell (efflux ratio =
1.4; Table 3-1) unlike loperamide (efflux ratio = 2.6), which was a positive efflux drug
for the activity of P-gp (data not shown). In addition, the permeability through the cell
membranes was dependent upon P-gp activity as determined by the lack of any change in
SMM-295 transport in the presence of verapamil (Table 3-1).
In vitro metabolism of SMM-295 was analyzed using a panel of biologically
relevant drug metabolizing CYP450 enzymes, including 1A2, 2C9, 2C19, 3A4, and 2D6.
To validate the metabolism of SMM-295 by each CYP450 enzyme used in the assay,
positive control compounds were assayed in conjunction with SMM-295. Specifically,
phenacetin (1A2), propranolol (2D6), diclofenac (2C9), lansoprazole (2C19) and
terfenadine (3A4) were tested due to well established metabolism through each respective
CYP450 enzyme. In summary, SMM-295 was metabolized by the CYP450 enzymes
over the 60 minute period in the following order (from highest to lowest): 2C19 > 3A4 >
2D6 > 2C9 > 1A2 (Table 3-2). The respective calculated half-lives for SMM-295 in the
presence of each CYP450 enzyme is provided in Table 3-2.
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Figure 3-1. Chemical structure and in vivo pharmacokinetics of SMM-295
(A) Chemical structure of SMM-295 is shown. (B, C) C57BL/6J mice were administered
6 mg/kg into the intraperitoneal space and blood and kidneys were harvested at the
appropriate time points shown in the graph. Plasma (B) and kidney tissue (C) levels of
SMM-295 were measured by LC-MS/MS, and half-life was calculated and graphed. n=3
mice per time point.
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Table 3-1.

Physiochemical and biochemical assays for SMM-295

Assay

Species

Receptor

Parameter

Values

CB1/CB2

Binding

Human

CB1

Ki

31

Human

CB2

Ki

Human

CB1

EC50

Human

CB2

EC50

Human

379 ± 53
nM
12 ± 2.26
nM
1,190 ±
22.1 nM
18.1 ±
1.45 nM
>99.9

Mouse
Human

10 PM

>99.9
4 +/- 3

Human
Human

1 PM
Papp A ÆB

Human

Papp B Æ
A

Human

Papp A Æ
B
(+
verapamil)
Papp B Æ
A
(+
verapamil)

cAMP
inhibition
Protein
binding (%
bound)
hERG (%
inhibition)
Permeability

Human

31

<0.1 %
5.2 ± 0.4
x 10-6
cm/sec
7.1 ± 1.2
x 10-6
cm/sec
7.9 ± 0.1
x 10-6
cm/sec
6.7 ± 0.2
x 10-6
cm/sec

Efflux
Ratio
(B-A/A-B)

66

1.4

0.9

Table 3-2.
Enzyme
Metabolism
Parameters

In vitro CYP450 enzyme metabolism
CYP1A2

CYP2D6

CYP2C9

CYP2C19

CYP3A4

Phenc
-etin

SMM295

Propranolol

SMM295

Diclofenac

SMM295

Lansrazole

SMM295

Terfenadie

SMM295

Half-life
(minutes)

49.3

> 60

< 5.0

28.4

9.0

55.3

7.4

6.8

19.0

12.2

%
Remaining
at 60
minutes
(+NADPH)

37

62

0

20

1

44

0

0

9

3
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Receptor Binding and Functional Assays
Measurement of CB1 and CB2 functional activities and receptor affinities of
SMM-295 were carried out using the ACTOne functional assay cell lines and membrane
preparations derived there from. The affinity of SMM-295 for CB2 was measured to be
12 ± 2.26 nM with 31-fold selectivity over CB1 (379 ± 53 nM; Table 3-1). The potency
of SMM-295 at CB2 was comparable to the affinity, with an EC50 of 18.1 ± 1.45 nM and
efficacy of 54% to prevent cAMP production (Figure 3-2). Compared to our internal
standard, SMM-295 was 2-fold less potent than CP 55,940 (EC50 = 8.74 nM), which had
a 77% efficacy to inhibit cAMP production. At much higher doses, SMM-295 could act
as a weak agonist of CB1 with an interpolated potency of 1,190 ± 22 nM and only 21%
suppression of cAMP at 1 μM (Figure 3-2A). In the parental cell line containing only
the cyclic nucleotide gated (CNG) ion channel, increasing concentrations of SMM-295
did not decrease the cAMP response, which confirmed that the observed cAMP response
was not due to off-target effects. Moreover, in the hERG assay, higher doses of SMM295 (10 PM) exhibited only minimal inhibition of the channel (4 ± 3%; Table 3-1).
Using ADMET Predictor, the calculated logP, S+logP, which has been a reliable
predictor for the ratio of lipid solubility to water solubility and for membrane-crossing
capability (Mannhold et al., 2009), for SMM-295 was 5 6 and the calculated water
solubility S+Sw was 0.0036 mg/mL. By comparison, another common CB2 agonist,
JWH-133, had considerably higher S+logP = 7.78 and lower S+Sw = 0.000019 mg/mL
demonstrating that SMM-295 had improved biophysical properties that could potentially
increase its ability to exert a biological response in vivo.
Rat NRK-52E proximal tubule cell line was incubated with increasing doses of
SMM-295 (0-10 μM) for 15 minutes and protein lysates were analyzed for changes in
ERK1/2, p38 MAPK and Akt activation by immunoblot analysis. Figure 3-2B shows
that there was a dose-dependent increase in the activation (phosphorylation) from 0 to 10
μM following exposure to SMM-295.
CB2 Receptor Upregulation in the Kidney Following Ischemia-Reperfusion Injury
Steady-state changes in the Cnr2 mRNA level were measured in a mouse model
of unilateral IRI. In the IRI-treated kidneys, Cnr2 mRNA increased after 24 hours (1.3 ±
0.2-fold; n=5) and reached significance by 72 hours (3.0 ± 0.2-fold; P<0.05; n=5)
compared to uninjured kidneys (Figure 3-3). The steady-state levels of CB2 mRNA
trended back towards normal levels at 168 hours after IRI (0.7 ± 0.3-fold; n=5).
Upregulation of Anti-Apoptotic Pathways Following CB2 Receptor Activation in
Kidney Lysates Obtained from Mice Following Renal Bilateral IschemiaReperfusion Injury
In the SMM-295 treated kidneys, increased activation of Akt (Ser473) and total
Akt was detected, which is associated with enhanced cell survival, compared to vehicle
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Figure 3-2. Functional activities of SMM-295
(A) Functional activities of SMM-295 in the CB2 ACTOne assay (open circles), CB1
ACTOne assay (open triangles), and parental ACTOne cells containing only the CNG ion
channel (filled squares). The functional activation of CB2 by the internal control (CP
55,940; filled diamonds) is shown. (B) Western blot analysis of signaling proteins after
brief exposure (15 minutes) to SMM-295 in rat NRK-52E proximal tubule epithelial
cells. Activation of pro-survival Akt/PKB and MAPK (ERK1/2 and p38) was detected
using specific antibodies. β-actin was used as a loading control. ERK1/2, extracellular
signal–regulated kinase 1/2.
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Figure 3-3. Increased steady-state levels of CB2 receptor mRNA in kidneys after
ischemia-reperfusion injury
Fold change of mRNA levels for CB2 receptor between contralateral and injured kidneys
from wild-type male C57BL/6J mice at various time points (24, 72, and 168 hours) after
unilateral IRI. n = 5 mice/group per time point. A t-test was used to confirm significant
differences (*P < 0.05) between contralateral versus IRI kidneys at each time point.
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treatment (Figure 3-4A-C). In addition, Bcl-2 (Figure 3-4A, D) and Bcl-xL (Figure
3-4A, E) was also markedly elevated in the SMM-295 treated mouse kidneys, which
provides evidence that SMM-295 would prevent apoptosis activation. This was
supported by a significantly lower number of TUNEL positive nuclei in the outer medulla
of were counted and graphed out of 1000 total nuclei counted in the sections. A t-test was
used to confirm significant differences (*P < 0.05) between groups. Scale bar, 100 μm
SMM-295 treated kidneys (1.3 ± 0.3%; n=5) compared to vehicle-treated kidneys (4.6 ±
0.6%; n=5) (Figure 3-4F-H). The molecular evidence using the mouse kidneys from the
in vivo studies would suggest that SMM-295 prevented tubular epithelial cell damage by
enhancing cell survival, in part by decreasing the activation of apoptotic cell death.
SMM-295 decreased the levels of CC3, a classic executioner of apoptosis, in NRK-52E
cells following hypoxic conditions (Figure 3-5A). This data provides direct evidence of a
decrease in apoptotic signaling molecules specifically on tubular epithelial cells using a
common in-vitro model of IRI.
Discussion
Consistent with our study, Nettekoven et al. (78) showed that their newly
synthesized CB2 receptor agonist could reduce circulating creatinine following renal IRI.
Moreover, a partial CB2 agonist, LEI-101, was capable of attenuating cisplatin-induced
tubular damage by reducing oxidative stress and inflammation in mice (80).
Administration of LEI-101 in mice deficient in the full-length CB2 receptor confirmed
that the CB2 receptor was responsible for the prevention of the cisplatin-dependent
tubular injury (80). In addition, we showed that an inverse CB2 agonist, SMM-189, could
exacerbate the tubular injury and promote renal damage. These studies provide strong
evidence that exogenous administration of cannabinoid agonists to the CB2 receptor can
protect the kidney during states of AKI. The mechanism by which the tubular epithelial
cells were protected by CB2 receptor activation needs further investigation, but it may
involve diverse signal transduction regulation of the various Gαβγ complexes in the
tubular epithelial cells. The CB2 receptor is well established to activate Gαi subunits to
inhibit cAMP production, but other studies have also shown that the CB2 receptor can
interact with Gαq to promote activation of phospholipase C (PLC), however this may be
an artificial effect that is caused by the construct GFP-CB2-βarrestin (145). PLC
activation is known to activate Akt, which is involved in promoting cell survival and
reducing the activation of pro-apoptotic pathways (146). Of these pathways, activation of
Akt can lead to increases in the anti-apoptotic proteins Bcl-2 and Bcl-XL, which was
observed in our study. Bcl-2 and Bcl-XL reside in the mitochondrial membrane and act
to promote cellular survival through the inhibition of actions initiated by other proapoptotic proteins that would otherwise cause a release of mitochondrial contents like
cytochrome c.(147). Cytochrome c from the mitochondria intrinsically activates caspase
3 leading to increased cleavage forms, which acts to degrade various cellular components
during apoptosis (148). Our study demonstrated CB2 activation in vivo leads to increased
phosphorylation of Akt with a concomitant increase in the Bcl-2 family proteins. This
subsequently reduced apoptosis in sub-lethally injured tubular epithelial cells, and this
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Figure 3-4. SMM-295 improved renal cell survival by reducing apoptotic
signaling
A) Representative Western blot analyses of pro-survival Akt (phospho- and total) and
anti-apoptotic Bcl-2 and Bcl-xL using protein lysates from mouse kidneys treated with
vehicle (n = 5) or SMM-295 (n = 5). β-actin was used as a loading control. Arrows on the
right indicate expected band size for the detected proteins. (B–E) Densitometric band
intensities were determined by ImageJ analysis for p-Akt (Ser473) (B), total Akt (C),
Bcl-2 (D), and Bcl-xL (E). (F and G) Representative images of TUNEL staining in
vehicle-treated (F) or SMM-295–treated (G) mice after IRI. (H) TUNEL-positive nuclei.
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Figure 3-5. Analysis of cleaved caspase-3 levels in NRK-52E cells following
hypoxic conditions in the presence of CB2 receptor activation
(A) Representative immunoblot images of cleaved caspase-3 levels in NRK-52E cells
following either normal or hypoxic conditions and administration with either vehicle or
SMM-295. * P<0.05 significant different between groups.
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could have accounted for the increase in function and decrease in tubular damage seen in
our study. Moreover, we confirmed that proximal tubular cells in vivo could suppress
CC3 levels following hypoxia in the presence of SMM-295. Further in vivo studies are
still needed to confirm that the signaling protein changes can be directly attributed to the
activation of the CB2 receptor and are not due to compensation by the injured renal cells
caused by activation or suppression of other pathways. Alternatively, the beneficial
effects of selective CB2 receptor activation may be attributed to a systemic effect
preventing immune cell recruitment to the sites of injury similar to the effects observed
during chronic kidney disease. The endocannabinoid system through the stimulation of
its cognate receptors, CB1 and CB2, has been shown to be involved in the regulation of
inflammation and immune function (149, 150). In particular, brain microglia, which are
proposed to be important in regulating the inflammatory response in the CNS, upregulate
expression of the CB2 receptor in response to a biological insult. It has been
demonstrated that CB2 ligands attenuate the adverse effects by reducing the release of
pro-inflammatory cytokines and chemokines (151-153), and also regulating the activation
state of microglia (112, 154). This biological effect is critical in the kidney, since the
immune system has been shown to be an important component of the early pathogenic
effects on renal cell damage, including vascular and tubular epithelial cells, which can be
attributed to resident and infiltrating immune cell activity (2, 6). Although our findings
are promising with regards to the potential therapeutic role of SMM-295 during the early
phase of AKI, further studies are needed to characterize other long-term changes in renal
architecture and function, such as urine concentrating mechanisms and vascular
abnormalities, to fully understand the positive impact of the CB2 receptor system during
kidney injury and recovery pathways. Therefore, future studies are necessary to elucidate
the possible signaling pathways associated with the CB2 receptor to produce the prosurvival effects in the kidney.
In our study, we synthesized SMM-295, which demonstrated highly selective
activation of the CB2 receptor that could provide beneficial protection of the renal
tubular epithelial cell structure and function. SMM-295 inhibited cAMP production and
also activated downstream MAPK signaling complexes consistent with the known actions
of CB2 activation. Pharmacokinetic analyses showed that SMM-295 had a relatively
short half-life. However, the short half-life for CB2 agonists remains a problem for most
of the well characterized analogs in the literature (100). There was, however,
accumulation of SMM-295 in the kidney, which could obviate the rapid decrement of
circulating drug and provide more opportunity for renal cell signal activation, particularly
during times of renal injury that would negatively impact clearance of exogenous drugs.
In conclusion, our group has demonstrated that SMM-295 is a selective agonist of
CB2 with comparable affinity, potency, and efficacy to other CB2 ligands, e.g. AM-1241,
HU-910, and LEI-101, which have previously been evaluated in kidney disease models.
In the following chapters the effects of CB2 activation by SMM-295 administration will
be determined in a commonly used pre-clinical mouse model of IRI. This study
demonstrates for the first time a direct effect of CB2 agonist on renal epithelial cells.
Although studies have shown an effect of cannabinoids on cell death in other organ
systems and cancer (155, 156), the effects of cannabinoid signaling on cell death can be
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quite diverse for a number of factors, including distinct cell types, concentration of ligand
used in the treatment, and disease models being evaluated. The complexity of the
endocannabinoid system provides an opportunity to develop therapeutic strategies
utilizing cannabinoid receptor ligands to treat a diverse array of diseases. We believe that
this study provides novel evidence of anti-apoptotic signaling mediated by CB2
activation in renal ischemic injury, in which early onset of cell death signaling cascades
and proliferation could play a large role in the pathophysiology of the disease. Moreover,
administration of SMM-295 immediately upon reperfusion after a brief renal ischemic
period reduced tubular epithelial cell damage in the outer medulla of the kidney. These
data would suggest that there is considerable promise in the development of SMM-295 as
a potential therapeutic, and that modifications to enhance its efficacy, potency and
selectivity to the CB2 receptor could lead to CB2 receptor selective agonist analogs that
will be clinically useful in the treatment of IRI and possibly other types of AKI.
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CHAPTER 4.

RENAL HEMODYNAMIC EFFECTS OF CB2 ACTIVATION3
Introduction

Acute kidney injury (AKI) is defined by an immediate loss in renal function due
to a number of factors, including the onset of sepsis, exposure to nephrotoxins, and organ
hypoperfusion due to ischemia (6). Ischemia-reperfusion injury (IRI) is one of the most
common forms of AKI and involves a complex series of cellular changes that can lead to
lethal tubular damage and loss of renal function in the most severe cases. The regulation
of renal blood flow dynamics to preserve glomerular filtration rate during AKI induced
by IRI is critical in the recovery of the kidney. To date, our understanding regarding the
mechanisms involved in regulating vascular function and hemodynamics in the kidney
during AKI needs further investigation.
Natural and synthetic cannabinoids have emerged in the past few years as a topic
of interest during normal and diseased states in the kidney, including AKI. Studies show
that the complete endocannabinoid system can be identified in various cells within the
kidney (158). The endocannabinoid system is comprised of endogenous molecules, Narachidonoylethanolamine (AEA) and 2-acylglycerol, both of its cognate G-protein
coupled receptors, cannabinoid type 1 and 2 receptors, and the enzymes involved in their
biosynthesis and catabolism (158). Moreover, there is impetus to understand the
biological activity of the cannabinoid receptors due to increased acceptance in the
medicinal purposes of cannabis and related compounds. The majority of studies to date
have focused upon the role of the CB1 receptors in the central and peripheral organs,
including the kidney, due in large part to its psychotropic and pain management effects.
In the kidney, however, the CB1 receptors consistently demonstrate deleterious effects on
glomerular and tubular function in various acute and chronic forms of injury. The role of
the cannabinoid receptors on the regulation of renal hemodynamics, even under normal
conditions remains poorly understand. Early rat studies implicated that anandamide
(AEA) increased renal blood flow with a concomitant reduction in glomerular filtration
rate by preferential vasodilation of the efferent arteriole via CB1 receptor activation (90).
Consistent with this finding, Deutsch et al. (92) demonstrated that segments of the renal
and arcuate arteries were capable of dilating in the presence of AEA through CB1
receptor stimulation. Conversely, a CB1 receptor using a synthetic agonist WIN 55212-2
demonstrated renal vasoconstriction (159). In addition, there is emerging new
developments in selective CB2 receptor activation, whereby their role in the kidney
generally opposes the effects by the CB1 receptor to protect renal function in the
glomerulus and renal tubules (83). As part of these findings, our group demonstrated that
the novel CB2 agonist, SMM-295, protects the renal tubular epithelial cells from severe
damage following renal ischemia-reperfusion injury by reducing pro-apoptotic signaling
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Modified from final submission with permission. Pressly, J. D., Soni, H., Jiang, S., Wei, J., Liu, R.,
Moore, B. M., & Park, F. (2019). Activation of the cannabinoid receptor 2 increases renal perfusion.
Physiological genomics, 51(3), 90-96 (157).
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(93). However, the effects by CB2 receptor activation has not been studied using this
compound on their potential to modulate renal vascular function.
While Chapter 3 focuses on direct effects of CB2 on tubular epithelial cell
survival, this chapter will focus on the hemodynamic effects of CB2 activation, which
may contribute to the survival of the tubular epithelial cells after injury. Additional blood
flow could provide protection from tubular injury and increase renal function following
IRI. For this reason, the present study was designed to evaluate the functional effects of a
novel selective cannabinoid CB2 receptor agonist to control the renal vasculature through
the use of laser Doppler flowmetry and changes in luminal diameters from isolated
perfused afferent arterioles.
Materials and Methods
Animals
C57BL/6J and Cnr2 knockout (B6.129P2-Cnr2tm1Dgen/J; stock #5786) mice
aged 10-12 weeks were obtained from the Jackson Laboratory (Bar Harbor, Maine).
Animal studies were approved by the Institutional Animal Care and Use Committee
(IACUC) at the University of Tennessee Health Science Center prior to performing any
procedures. All mice were provided ad libitum access to food and water prior to and after
the surgical procedures and were kept on a 12 hr/12 hr light/dark cycle during the course
of their housing in the animal facilities.
Chemicals and Assay Kits
Indomethacin (cat #I7378), capsaicin (cat #M2028), and Nw-Nitro-L-arginine
(LNNA; cat #N5501) were obtained from Millipore Sigma (St. Louis, MO). Cremophor
ELP was purchased from BASF. SMM-295 was synthesized by Dr. Bob Moore as
previously described by our group (93). Mouse calcitonin gene related peptide (CGRP)
ELISA (cat #E0056Mo) was obtained from Bioassay Technology Laboratory (Shanghai,
China) and performed according to the manufacturer’s protocol.
Isolated Perfused Afferent Arteriole Measurement of Luminal Diameter
Measurements of the afferent arteriole luminal diameter were performed using
isolated perfused mouse afferent arterioles as previously described (160-164). In brief,
the afferent arterioles with attached glomeruli were isolated and transferred to a
temperature regulated chamber mounted on an inverted microscope in media. A set of
micropipettes held the glomerulus and cannulated the afferent arterioles holding the
intraluminal pressure at 60 mmHg. The arteriole preparations were then incubated with

42

Norepinephrine (1 μM) and/or SMM-295 (5 μM) for 15-minute periods during the
measurement of the intraluminal diameter.
Animal Surgeries
A total of 72 mice were used in this study which utilizes both survival (bilateral
ischemia-reperfusion injury) and non-survival surgical techniques (terminal anesthetized
hemodynamic and CGRP analysis) using protocols that have been well established and
published by our laboratories (72, 93, 115, 116, 165)
Hemodynamic Analysis
Renal cortical perfusion and mean arterial blood pressure measurements was
conducted using techniques published by our group (166, 167). A total of 30 mice were
anesthetized with a combination of ketamine (100 mg/kg)/xylazine (10 mg/kg) mixture
i.p. and re-administered as needed throughout the procedure to maintain a constant level
of anesthesia. Catheters were placed into the jugular vein for infusion of drugs using an
infusion pump, and carotid artery to measure arterial blood pressure (ADInstruments,
Colorado Spring, CO). Laser Doppler probes were calibrated with a standard calibration
device using a motility standard (Perimed, Jarfalla, Sweden) such that 1 Perfusion Unit
(PU) corresponds to an analog output of 10 mV. The kidney was isolated, and a Doppler
probe is placed on the surface of the kidney attached to a holder to measure cortical renal
blood flow. Cortical renal blood flow was measured and analyzed using a PowerLab data
acquisition system and LabChart software (ADInstruments) and allowed to come to a
steady baseline level prior to any pharmacological manipulations. Indomethacin (1
mg/kg) and L-NG-Nitroarginine (LNNA; 10 mg/kg) were administered i.p. 15 minutes
before infusion of SMM-295 or vehicle [EtOH (5%): Cremophor ELP (5%):saline
(90%)]. Capsaicin (50 mM) was applied using a cotton tipped applicator for 15 minutes
to the isolated renal vein and the animal rested for 90 minutes following capsaicin
treatment. Subsequently, the vessels and surrounding tissues were washed with saline
solution and allowed to rest for an additional 60 minutes prior to SMM-295 infusion as
previously described by Peixoto-Neves et al. (167). SMM-295 or vehicle were
administered via infusion pump with a volume of 1 mL over a 10-minute period. At the
end of the experiment, plasma was collected by cardiac puncture with a 23-gauge needle
and 1 mL syringe, and the animal was euthanized by collecting the remainder of the
tissues.
Calcitonin Gene-Related Peptide (CGRP) ELISA
A total of 12 mice were anesthetized with a mixture of ketamine (100
mg/kg)/xylazine (10 mg/kg). An indwelling catheter was placed into the jugular vein for
infusion with SMM-295 (n=6) or the vehicle solution (n=6) using an infusion pump at a
rate of 0.1 mL/min for 10 minutes. Blood was collected from the inferior vena cava after
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clamping with microisolator clips immediately above the renal veins. The detection for
CGRP was performed using a commercially available mouse CGRP ELISA kit.
Bilateral Ischemia-Reperfusion Injury (IRI)
A total of 18 mice were anesthetized with pentobarbital (50–80 mg/kg i.p.) before
IRI was performed. Flank incisions were made on both sides of the mice, the kidneys
were isolated and the renal hilus was clamped. The renal ischemia was maintained for
24.5 minutes to and immediately upon removal of the microisolator clamps to initiate
reperfusion either with CB2 receptor agonist, SMM-295 (6 mg/kg i.p.; n=6) or vehicle
(Cremophor; n=6) was administered. The kidneys were subsequently monitored for
restoration of blood perfusion prior to closure of animal. All surgeries were conducted
under aseptic conditions and all mice were administered buprenorphine for pain
management and antibiotics, if needed, after the surgery and during the remainder of the
experimental period. After 24 hours, another dose of vehicle or SMM-295 (6 mg/kg i.p.)
was administered to each of the mice. Plasma was collected every 24 hours following
IRI. The mice were euthanized after 48 hours following terminal anesthetized laser
Doppler flow measurements.
Statistics and Study Design
The data and statistical analysis comply with the recommendations on
experimental design and analysis in pharmacology (Curtis et al., 2015). All values are
shown as means ± S.E.M. using GraphPad Prism software (version 6.0; GraphPad Inc.,
La Jolla, CA). An unpaired t-test or one-way analysis of variance was performed using
Bonferroni post hoc analysis to confirm significant differences (P < 0.05) between animal
groups. Post-hoc analysis was performed only in the groups where F achieved P < 0.05
and there was no significant variance in homogeneity. The ARRIVE guidelines were
used to design animal experiments as a standardized approach to ensure validity and
reproducibility of results.
Results
SMM-295 Effect on Cortical Renal Perfusion
Laser Doppler flowmetry was performed to detect changes in renal cortical
perfusion in anesthetized C57Bl/6J mice following the administration of a novel CB2
receptor agonist, SMM-295 (see chemical structure in Figure 4-1A). Administration of
SMM-295 (6 mg/kg) or vehicle solution was infused into an indwelling jugular vein
catheter over a 10-minute period at a rate of 0.1 mL/min. Renal perfusion was monitored
for a 30-minute period and vehicle treatment led to an insignificant increase in the renal
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Figure 4-1. CB2 receptor agonist, SMM-295, promotes increased renal cortical
perfusion
A) Chemical structure of D9-THC and SMM-295. (B) Measurement of renal cortical
perfusion by laser Doppler flowmetry and (C) mean arterial pressure following
intravenous infusion of vehicle (veh; n=10) or SMM-295 (6 mg/kg; n=7) in anesthetized
C57BL/6J mice, and SMM-295 (6 mg/kg; n=6) in Cnr2 knockout mice. Data was
graphed as a percent change from baseline levels in each mouse. * P<0.0001 significant
difference in cortical perfusion for both groups (B, C) and only vehicle group for MAP
(C); ** P<0.05 significant difference between WT and Cnr2 KO mouse.
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perfusion by 1.1 ± 10.6 units (0.1 ± 1.5% from baseline levels) (Figure 4-1B). Infusion
of SMM-295 (6 mg/kg) resulted in a significant increase (P<0.0001) of 136.1 ± 8.9
perfusion units (or 13.8 ± 0.6%) from the baseline levels. Mean arterial pressure
following administration of SMM-295 (6 mg/kg IV) resulted in a significant reduction of
19.0 ± 2.8 mmHg (P<0.0001; n=7) compared to vehicle (-1.3 ± 1.1 mmHg; n=10) (Fig.
1C). Cnr2 knockout mice only reduced blood pressure by 9.1 ± 2.3 mmHg (n=6) similar
to the changes measured with met-anandamide (-7.3 ± 2.6; n=6; data not shown).
To exclude the possibility of the CB1 receptor, a highly selective CB1 receptor
agonist, met-anandamide, was infused at the same dose (6 mg/kg) into a separate group
of anesthetized mice (Figure 4-2). In these mice, there was nearly no change in the renal
cortical perfusion following administration of met-anandamide (Δ in perfusion units = 3.6 ± 12.0 or -0.7 ± 1.9% from the baseline levels; n=6 mice) compared to the baseline
levels. In addition, we examined the effect of SMM-295 using a genetic Cnr2 knockout
mouse to confirm the selectivity of the CB2 receptor agonist (Figure 4-1B). Indeed, the
change in cortical perfusion following intravascular administration of SMM-295 into the
Cnr2 knockout mice resulted in an insignificant increase in perfusion units (24.0 ± 21.7)
or 2.7 ± 2.0% change from baseline levels (n=6 mice). HU-308 (6 mg/kg), a selective
CB2 agonist, was found to have a modest increase in renal cortical blood flow by 6.9 ±
1.5% (P<0.05; n=6) demonstrating the role of the CB2 receptor in blood perfusion.
CGRP Levels Following SMM-295 Infusion
Plasma was isolated from blood collected from the renal vein to measure CGRP
levels by ELISA (Figure 4-3A). In vehicle-treated mice, SMM-295 induced a significant
increase (P=0.0068) in plasma CGRP by 44% to 64.5 ± 3.9 ng/L (n=6) from 44.7 ± 2.2
ng/L (n=6) in the vehicle treated mice.
To block the effects of CGRP release from afferent nerve terminals, capsaicin was
applied to the renal nerves prior to the administration of SMM-295 into the anesthetized
mice. Renal cortical perfusion was significantly lower (P<0.0001) at 38 ± 9.7 units (or
4.4 ± 1.1% from baseline period; n=6 mice) following administration of SMM-295 (6
mg/kg) into the jugular vein compared to non-capsaicin treated mice (Figure 4-3B).
Role of Cyclooxygenase and Nitric Oxide Synthase in CB2 Receptor Renal
Perfusion
To test whether cyclooxygenase products were involved in promoting the increase
in cortical perfusion following stimulation of the CB2 receptor, we administered a single
dose of indomethacin (1 mg/kg IP) 20 minutes into the anesthetized mouse prior to
injection of SMM-295 (6 mg/kg). The increase in cortical perfusion (131.5 +/- 8.6 units
or 14.4 +/- 1.5% from baseline levels; n=6) by SMM-295 was not different in the
presence of indomethacin compared to the SMM-295 group (Figure 4-4). As an alternate
mode of action, we investigated whether nitric oxide could play a role in
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Figure 4-2. Increased cortical renal perfusion is not through the CB1 receptor
Measurement of renal cortical perfusion by laser Doppler flowmetry following
intravenous infusion of met-anandamide (Met-ANA; 6 mg/kg; selective CB1 receptor
agonist; n=6) and HU-308 (6 mg/kg; selective CB2 receptor agonist; n=6) in anesthetized
C57Bl/6J mice. Data for the vehicle (control) was re-graphed from Figure 4-1 and was
shown as a percent change from baseline levels in each mouse. * P<0.05 significant
different from control group.

Figure 4-3. Renal afferent nerve activation is involved in CGRP release and
increased cortical renal perfusion
(A)Plasma CGRP levels was measured by ELISA from C57BL/6J mice infused with
either vehicle or SMM-295 (6 mg/kg). n=6 mice per group. * P=0.0068 significant
difference between groups. (B) Measurement of renal cortical perfusion by laser Doppler
flowmetry during control and SMM-295 (6 mg/kg) administration in mice treated with
capsaicin to ablate renal afferent nerve activity. N=6 mice per group. P<0.0001
significant difference between groups.
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Figure 4-4. Endothelial derived factors COX and NOS are not involved with the
increase in cortical renal perfusion following SMM-295 administration
Change in cortical renal perfusion units using SMM-295 (6 mg/kg IV) as graphed by
percent change from baseline levels following pre-treatment with indomethacin (INDO; 1
mg/kg IP; n=6) or L-NNA (10 mg/kg IP; n=7) in C57Bl/6J mice. P<0.01 significant
difference between LNNA and the other two groups. Data for the vehicle and SMM-295
was re-graphed from Figure 4-1 and was shown as a percent change from baseline levels
in each mouse.
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controlling renal perfusion due to SMM-295. Similarly, blockade of nitric oxide synthase
(NOS) was achieved using L-NNA pre-treatment 20 minutes prior to the administration
of SMM-295 (6 mg/kg). The increase in the cortical perfusion promoted by SMM-295
was not reduced by the inhibition of NOS (n=7), but it was significantly higher (P<0.01)
than SMM-295 treated mice with either vehicle or indomethacin pre-treatment.
SMM-295 Increases Luminal Diameter of Afferent Arterioles
Afferent arterioles were isolated from the mouse and placed into a bath solution
for perfusion to pressurize at 60 mmHg. Under these basal conditions, the luminal
diameters were measured in the presence of the control solution at 12.9 ± 0.41 μm
(Figure 4-5D). To determine whether SMM-295 promoted a vasoconstriction on the
isolated afferent arterioles, SMM-295 (5 PM) was applied to the bath solution and did not
result in any changes in the luminal diameters during the two separate, but consecutive
15-minute incubation periods. Both of the luminal diameters remained similar to the
control period (13.19 ± 0.42 and 13.22 ± 0.36 μm, respectively; n=4).
To test whether SMM-295 could dilate afferent arterioles, the vessels were preconstricted with norepinephrine (NE; 1 μM) for 15 minutes, followed by addition of
either SMM-295 (5 PM) in the bath solution (Figure 4-5F) or vehicle (Figure 4-5E) in
the presence of NE (1 μM). As shown in Fig. 4-5B, E, the luminal diameters of the
afferent arterioles were significantly decreased (P=0.0019) from 12.71 ± 0.83 μm to 7.94
± 0.73 μm following application of NE (n=4). The afferent arteriole remained constricted
8.06 ± 0.64 μm in a subsequent 15-minute period with the vehicle. In the presence of
SMM-295 (5 PM), afferent arteriolar diameter significantly increased by 37 ± 7%
(P<0.0001) to 10.41 ± 0.55 μm from the NE pre-constricted state of 7.62 ± 0.37 μm
(Figure 4-5E). All of the changes in the luminal diameter occurred within 5 min after the
addition of each individual drug or combination of drugs.
SMM-295 Effect on Cortical Renal Perfusion Following IRI
In a separate group of C57Bl/6 mice, bilateral ischemia-reperfusion injury was
initiated and either vehicle or SMM-295 (6 mg/kg IP) was administered immediately
after removal of the clamps to allow for reperfusion of the ischemic kidneys (Figure
4-6). Daily injections were made with either vehicle or SMM-295 for a period of 48
hours at which point the mice were anesthetized to measure the cortical perfusion. As
shown in Figure 4-6, the sham-operated (no IRI) mice for a period of 48 hours exhibited
cortical perfusion of 979.6 ± 73.3 units (n=6), which was considerably higher (P=0.0002)
than the IRI-treated mice administered vehicle (604.8 ± 31.1 units; n=6). Administration
of SMM-295 (6 mg/kg IP once a day) was measured to have cortical perfusion similar to
the sham-operated mouse kidneys measurements (1005.9 ± 62 units; n=6).
w
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Figure 4-5. SMM-295 increases luminal diameter of pre-constricted isolated
perfused afferent arterioles
Afferent arterioles were isolated from C57Bl/6 mice and perfused to measure luminal
diameter changes during basal, norepinephrine (NE; 1 μM) and SMM-295 (5 μM) (A-C)
Representative images of the isolated afferent arterioles during (A) basal (control), (B)
NE, and (C) NE + SMM-295. (D-F) Graphical analyses of the luminal diameter changes,
if any, during the following conditions: (D) SMM-295 incubation during 2 consecutive
periods (15 minutes each period); (E) NE incubation during 2 consecutive periods (15
minutes each period); (F) NE incubation during the first period, and NE + SMM-295
during the second period. N = 4 arterioles per group. * P=0.0019 significant difference
between NE treatment with or without vehicle; ** P<0.001 significant difference between
NE alone and NE + SMM-295 groups.
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Figure 4-6. Daily administration of SMM-295 prevented the reduction in renal
cortical perfusion following bilateral renal IRI
Renal cortical perfusion was measured using laser Doppler flowmetry in normal and IRItreated C57Bl/6J mice (n=6 mice/group) administered vehicle or SMM-295 (6 mg/kg IP)
every 24 hours for 2 days. N=6 mice per group. * P=0.0002 significant difference
between the other two groups.
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Discussion
This is the first study to demonstrate that SMM-295, a novel selective
cannabinoid CB2 receptor agonist, has the capability to increase renal cortical blood
floand also promote direct vasodilation of isolated perfused afferent arterioles. Due to the
absence of an effective and selective neutral CB2 receptor antagonist, our
pharmacological findings were confirmed by evaluating our CB2 agonist in a genetic
Cnr2 knockout mouse model on the C57Bl/6J background. Previous studies have
primarily investigated the effects of synthetic and endocannabinoids to control renal
tubular and excretory function, but little was investigated regarding vascular effects (83).
Early studies evaluating the biological function of the endocannabinoid, AEA, which has
activity at both CB1 and CB2, show a putative vasodilator effect in the kidney leading to
reduced renal vascular resistance (90, 92). These studies demonstrate that the primary
receptor responsible for this effect was CB1 (90, 92), which is similar to other published
studies using similar endogenous and synthetic cannabinoid receptor analogs to evaluate
central and peripheral vascular bed regulation through the CB1 receptor (168).
Alternatively, there is evidence that AEA increased renal blood flow changes and
urine excretion through a non-CB1 dependent mechanism (95). Conversely, there are
conflicting studies that provide evidence that CB1 can have an opposite effect to produce
vasoconstriction in the kidney (159) or no effect on renal hemodynamics (94). Similar to
our results, Li and Wang (94) showed that renal cortical and medullary blood flow was
non-responsive to direct intramedullary administration of a highly selective CB1 agonist,
met-anandamide. Moreover, Koura et al. (90) could not fully explain the increased
vasodilation of the afferent arteriole solely to the CB1 receptor but may have involved a
non-CB1 receptor. This would be consistent with our findings where CB2 receptor
stimulation with SMM-295 increased luminal diameter of the norepinephrine preconstricted isolated perfused afferent arterioles. The direct vasodilator effects by CB2
receptors has also been reported in other vascular beds, including the mesenteric arteries
(169) and cerebral vasculature (170). It may be possible that other cannabinoid binding
proteins, such as TRPV1, GPR18 or GPR55, could also indirectly be activated to increase
their function to promote changes in the systemic and regional vasculature either alone or
in concert with the non-CB1 receptors (171-173). However, there is evidence that GPR55
may have no effect on the anandamide-dependent vasodilation, at least in mesenteric
arteries (172).
Using the intact kidney in the anesthetized mouse, we confirmed that there is
increased renal cortical blood flow mediated by SMM-295 through the activation of the
CB2, but not the CB1 receptor. This effect may be attributed to dilation of peripheral
blood vessels on CB2 receptors, including those in the kidney, since a marked reduction
in mean arterial pressure was associated with the increased renal perfusion mediated by
SMM-295. Moreover, there was a lesser increase in renal perfusion by SMM-295 in Cnr2
knockout mice with reduced change in blood pressure. In previous studies and in our
present study, the CB1 receptor stimulation reduces blood pressure using specific
agonists either by direct vascular effect or vagal stimulation (94, 174), but there is no
change in renal cortical perfusion (94).
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Moreover, the effect of SMM-295 to mediate this effect may not be solely due to
its effects within the kidney but contributed by sensory nerve activation outside of the
kidney. Prior studies showed that drugs non-selective at CB1/CB2, such as U9-THC and
WIN 55,212-2, can augment release of CGRP (175, 176), which can promote rat
mesenteric arterial bed dilation (176). Other studies showed that CB2 receptors can
mediate the release CGRP for attenuation of osteoarthritic knee joint pain and in the rat
spinal cord (177, 178), but these effects may not be universally confirmed (179). In our
study, SMM-295 produces an increase in calcitonin gene-related peptide (CGRP) levels
from blood collected immediately flowing out of the renal vein. CGRP is known to be a
potent vasodilator and released at the nerve terminals of sensory nerves to regulate blood
vessel tone (180, 181). The mechanisms by which CGRP can promote vasorelaxation
remains to be fully understood, but it has been suggested that the primary mode of action
is through a cAMP-dependent activation of protein kinase A (PKA) to open potassium
(K+) ion channels (180, 181). The subsequent hyperpolarization of the cell membrane
leads to dilation of the smooth muscle cells surrounding the blood vessels. This may be
the mode of action in the kidney, since we were unable to determine any reduction in
blood flow by pre-treating the mice with either indomethacin or L-NNA to prevent the
production of vasodilator prostaglandins and nitric oxide, respectively. Previous studies
have documented that CGRP may activate other second messenger systems to increase
the production and release of nitric oxide (180, 181). Further studies will be needed to
ascertain the mechanism by which CB2 receptor activation of the sensory nerves leading
to the kidneys regulate cortical hemodynamics.
Perspectives and Conclusion
With the increasing societal acceptance in drugs that activate cannabinoid
receptors for medicinal use, it is essential to better understand the biological function of
these receptors, particularly the CB2 receptor in the control of renal function. In the
kidney, there is increasing data to demonstrate that activation of the CB2, and not CB1
receptor, can play a crucial role in protecting renal tubular and vascular cells during acute
injury or chronic disease states (83). Moreover, the negative psychotropic effects of
cannabinoid receptor activation is exclusive to the CB1 receptor. For this reason, the
development of CB2 receptor agonists remains an area of intense research. A recent
review of the commercially available CB2 agonists re-validated for their selectivity and
efficacy to identify only a handful of CB2 agonists as “gold standard” (182). Even the
most optimal CB2 receptor agonists have their limitations in terms of their selectivity,
high metabolism in vivo, and lack of testing for their efficacy in animal models in vivo.
Our recent work using our newly synthesized CB2 receptor agonist, SMM-295,
demonstrated a protective effect to reduce renal tubular epithelial cells damage following
AKI by decreasing apoptotic signaling (93). The current study builds upon our
knowledge about SMM-295 by showing its ability to increase renal cortical perfusion and
promote afferent arteriolar dilation. Further studies are needed, however, to better
understand the role of CB2 receptors in the regulation of blood flow distribution in the
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kidney between the renal cortex and medulla, and also whether there are direct effects to
control GFR.
In conclusion, our study has provided the first evidence for CB2 receptor
activation to promote increased renal perfusion, and this receptor should be further
evaluated in pre-clinical studies for its beneficial effects in other acute and chronic
disease models of the kidney.
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CHAPTER 5.

DISCUSSION

Researchers have been studying the cannabinoid system for decades to understand
their role in homeostatic and disease mechanisms throughout the body. To optimize the
use of cannabinoid receptor binding compounds to promote beneficial effects in the
kidney, a plethora of synthetic cannabinoids have been designed and synthesized for
testing in the kidney and other organs. These compounds have various selectivity and
activity at both the CB1 and CB2 receptors having different effects depending on the
compound structure. Our studies focus on a novel CB2 selective agonist SMM-295 which
displays unique properties compared to conventional synthetic CB2 agonists, JWH-133,
and HU-308. Our study functions to contribute to the increasing volume of knowledge
into how the cannabinoid system plays a role in renal function and repair from injury and
categorizes the effects of the novel compound SMM-295 administered following IRI.
SMM-295 demonstrated an ability to decrease injury and increase renal function
following IRI by decreasing the apoptosis levels in tubular epithelial cells through
activation of CB2. Our initial investigation into the effects of CB2 activation was
justified by several studies demonstrating a protective effect of CB2 agonists in AKI (7683). Our results proved consistent with these studies using a novel CB2 agonist, SMM295. The CB2 receptor can activate PLC which activate AKT leading to increased cell
survival though activation of anti-apoptotic cascades (145, 146). In our studies, apoptosis
was decreased by an associated increase in AKT signaling of BCL-2 family of proteins,
which are known to stabilize the mitochondrial membrane preventing the release of
cytochrome c, which initiates apoptotic pathways. (147, 148). Apoptosis is a primary
mechanism of cell death in tubular epithelial cells in response to ischemic injury as well
as other types of AKI (183, 184), including nephrotoxic insults that can be detected by
measuring indicators, such as caspases and p53 levels at various early time points upon
exposure to the injury stimuli (2). Our data demonstrate that SMM-295 is a moderately
selective agonist of CB2 with comparable affinity, potency, and efficacy to other CB2
ligands (e.g., AM-1241, HU-910, and LEI-101) which have previously been evaluated in
kidney disease models (76-82). Future studies aimed at determining the full cascade
leading to a reduction in apoptosis could uncover novel potential targets for future studies
and therapeutic applications. Additionally, consequent studies should also investigate the
effectiveness of SMM-295 in other models of renal injury, including cisplatin and sepsisinduced AKI.
While this effect can explain the decrease in tubular damage following ischemic
injury in SMM-295 treated mice, we recognized that there also could be a hemodynamic
effect driving the increases in renal function seen in these mice. Increases in renal
perfusion and subsequently, GFR provides an additional mechanism to protect tubular
epithelial cells from injury. Restoration of renal blood flow and increased oxygen through
increased blood supply provides relief to injured cells that are acting to survive and
contribute to renal function following the insult. Increases in renal perfusion lead to
increases in medullary oxygen levels (185). This region is particularly susceptible to
hypoxia and damage in this region can lead to increasing and persistent hypoxic
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conditions following injury (2). Our novel compound provides protection from apoptosis
by a direct effect on proximal tubule cells and indirectly through increased renal
perfusion. These effects could potentially provide a synergistic role in preventing renal
damage and maintaining renal function following injury. There are other clinical studies
being developed to target either the blockade of apoptosis or increase renal perfusion, but
not concurrently, to determine their effectiveness as a treatment modality for AKI (186).
Our data confirmed that there is increased renal cortical blood flow mediated by
SMM-295 through the selective activation of CB2. Mean arterial pressure also reduced
with SMM-295 administration indicating the effect of increased renal perfusion by
SMM-295. Other studies have demonstrated cardiovascular effects of both CB1 and CB2
agonists, which can lead to dilation of peripheral blood vessels in the kidney as well as
other organs in the body (90, 92, 94, 95, 159, 169, 170, 187). These studies, however,
showed this effect was caused by CB1 and non-CB1/2 mechanisms. Our study also
demonstrates that SMM-295 produces an increase in CGRP consistent with other studies
that demonstrate nonselective CB1/CB2 agonists can cause changes to CGRP release
promoting vasodilation (175, 176). Vasodilation of renal arterioles led to an increase in
renal perfusion in our study which could prove beneficial in treating AKI by possibly
increasing GFR. AKI is defined by a sudden decrease in GFR and thus increasing GFR
should be the goal for treatment of AKI in the clinical setting. The increase in renal
perfusion demonstrated in our study could alter GFR, however, this was not a parameter
that was directly measured. It is possible that SMM-295 does not affect GFR, but only
blood flow dynamics, due to regulatory mechanisms that underlie the control of GFR,
such as concurrent vasodilation of efferent arterioles (2).
While multiple CB2 agonists have demonstrated beneficial effects in AKI, SMM295 is the first compound that also demonstrates beneficial effects on renal
hemodynamics. This unique property of SMM-295 may be attributed to the differential
ability of different CB2 agonists to bind to various active states of the CB2 receptor. This
concept is known as biased signaling or functional selectivity and is an emerging area of
interest being incorporated into drug design (108). The idea is that GPCRs have various
active and inactive confirmations that they are cycling through randomly even if just by
Brownian motion (188). Each of these active or inactive confirmations have specific
binding pockets that can preferentially bind to different molecules (i.e., antagonists,
agonists, and inverse agonists) leading to stabilization of the confirmation. These
different active confirmations also have different signaling outputs, whether it be through
mechanisms like cyclic AMP, GIRK activation, GTPase activity or receptor
internalization through β-arrestin recruitment (189). Therefore, different therapeutics
aimed at a particular receptor can be investigated for their ability to interact with specific
active or inactive states stabilizing these confirmations in leading to particular
downstream effectors of interest. In unpublished data our lab demonstrated that HU-308
had no effect on renal perfusion or blood pressure. This could be because HU-308 is
known to have preference for GIRK channels while other CB2 agonists like SMM-295
and JWH-133 have not been established to show GIRK activity (100). Therefore, the
effect seen by SMM-295 is established through other mechanisms outside of a potassium
channel opening. Furthermore, the mechanism through which SMM-295 could impact
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renal hemodynamics may be even more complicated than first assumed. Cannabinoid
receptors are known to dimerize with other receptors, notably dopamine receptors, and
this dimerization could be the effector stimulus on the sensory nerves that could drive the
changes seen in renal hemodynamics (190). Future studies should act to employ multiple
methods including western bot analysis, ELISA, and FRET analysis will identify the
ability of novel CB2 agonists to respond through different signaling outputs including
cAMP accumulation, ERK phosphorylation, GIRK activation, GTPγS binding, and βarrestin recruitment (191, 192). Future studies investigating the functional selectivity of
SMM-295 compared to other CB2 agonists will enhance our understanding of the
behavior of these compounds at CB2 and enable the development of novel agonists
designed to address multiple disease state pathologies.
Interestingly, during our studies monitoring renal perfusion, we notice that blood
pressure also decreases in response SMM-295. Administration of SMM-295 to Cnr2-/mice resulted in a decrease in blood pressure, but this decrease was only half of the
magnitude seen in WT mice. There may be in fact multiple mechanisms governing
systemic hemodynamics mediated by CB2 activation that could include off target effects
and possibly activation of other cannabinoid targets, such as the hypothesized endothelial
cannabinoid receptor, CBe, that could be implicated in systemic blood pressure
regulation (193-195). Additionally, while SMM-295 has increased selectivity for CB2
over CB1, SMM-295 still has some activity at CB1. It is known that THC which has
activity at both CB1 and CB2 can decrease blood pressure (187). In animals that lack the
CB2, SMM-295 may still retain activity at CB1 which is known to have hemodynamic
effects in the body that could explain the effect seen in the Cnr2-/- mice (187). Therefore,
the hypotensive effects of THC may in fact be due to both CB1 and CB2 activity instead
of CB1 activity alone based on the data in our studies. Further studies should be aimed at
uncovering the full mechanism of the effect of SMM-295 on systemic blood pressure.
More interestingly, while the effect on renal blood flow can be blocked by ablation of the
renal nerve, the blood pressure decreasing effect of SMM-295 remains intact. This may
be due to differences in CB2 receptor expression between cells of different tissues (196,
197). At present, there is limited data pertaining to the expression patterns of CB2
receptors due to inadequate tools to detect the receptor. However, a recent paper
described the invention of a novel transgenic mouse model which expresses eGFP under
the same promoter as Cnr2 (198). This mouse model is novel in that it enables scientists
to determine in real time the expression of CB2 within different cell types by simply
detecting fluorescent levels corresponding to eGFP expression. Therefore, we can better
answer what cell types express CB2 and how this expression pattern changes in models
of disease. Further understanding of these alternate modes of action may provide greater
insight into the systemic effects of SMM-295 on blood pressure through the effects of
CB2 activation.
In conclusion, this body of work demonstrates a beneficial effect of CB2
activation following IRI. Additionally, the novel CB2 selective agonist, SMM-295,
provides additional benefits over current commercially available CB2 agonists. The
employment of various CB2 agonists with various functional properties in AKI may be
required in the clinic due to different properties of the drugs to mitigate the effects of
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AKI. For example, patients who experience AKI that have compromised cardiac function
would benefit from a CB2 agonist that does not decrease blood pressure like SMM-295.
Therefore, we need more data about different and novel CB2 agonists to treat AKI using
exogenous cannabinoid system activation effectively. Our studies along with future
investigation of the localized effects of CB2 agonists throughout the body will continue
to provide the crucial foundation for the use of therapeutics targeting the cannabinoid
system which is becoming a rapidly evolving area of interest in various renal pathologies
including AKI.
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